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Introduction 
   
 
 
Among neurological diseases, sleep disorders are those commonly considered to be less serious 
and disabling. For this widespread belief, often people are poorly inclined to report their sleeping 
problems  to  their  personal  health-care  provider.  However  these  disturbances  affect  a  large 
segment of world’s population. Their prevalence has been estimated to be approximately 10%.  
The  causes  of  sleep  problems  are  different  and  often  are  consequences  of  other  clinical 
conditions. Whatever the causes are, it has been demonstrated that sleep deprivation affects the 
overall life quality, resulting in impaired memory and cognitive functions and compromising both 
productivity and wellness. Sleep disturbances constitute therefore a substantial socio-economic 
burden and, for this reason, the appropriate diagnosis and treatment of these pathologies represent 
great  challenges  for  clinicians  and  pharmaceutical  companies.  The  latter  have  made  huge 
investments in this research field, trying to develop safer and more effective drugs (hypnotics) 
able to regulate the sleep-wake alternation. Sleep is not a homogeneous state of unconsciousness, 
but it is characterized by an internal structure, called ‘sleep architecture’, described by different 
sleep stages (awake, stage 1, stage 2, deep sleep, REM) and transitions among them. It has been 
demonstrated  that  sleep  architecture  follows  specific  patterns  during  the  night  and  that  the 
maintenance of such structure is important to guarantee a restorative sleep.  
Sleep  stages  are  commonly  assessed  through  ‘polysomnography’,  a  multi-channel  diagnostic 
technique  which  consists  in  the  simultaneous  recording  of  electroencephalogram, 
electrooculogram, electromyogram and other relevant features. On the basis of the characteristics 
of these recordings, international regulatory authorities provided indications on the endpoints to 
be evaluated for assessing the severity of the sleep conditions and the effect of drugs for the relief 
of these conditions. In this context, aggregated variables characterizing each patient’s sleep, such 
as the 'Wake After Sleep Onset', (WASO, the amount of time during the night spent in the awake 
state after being fallen asleep), or the ‘Latency to Persistent Sleep’, (LPS, the time spent in the 
awake state before falling asleep), are typically used. In the clinical practice, sleep disorders and, 
in turn, the effect of hypnotics are described on the basis of these aggregated parameters which, 
anyway, reflect only the overall trend of sleep during the night. Transforming the PSG data into 
these aggregate parameters implies however a substantial loss of information regarding the sleep 
architecture. On the contrary, the recent research has demonstrated that the maintenance of a 
physiological sleep architecture is just as important as the total sleeping time, so that this is an 
important differentiation criteria for new drugs used for the treatment of sleep disturbances.  . 
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In  the  effort  of  better  understanding  the  sleep-wake  cycle,  mathematical  models  should  be 
considered as a natural way to properly and quantitatively integrate complex information obtained 
from brain and sleep studies. In particular, it would be suitable to describe the sleep architecture 
through a mathematical model, to correctly describe and/or predict the sleep stages time-course 
along the night. In this respect, the polysomnograghic data can be described using a finite discrete 
stochastic process assuming values in a finite discrete set (the sleep stages). One of the most 
interesting approaches proposed in the literature to describe such data [1] is the ‘Markov-chain 
model’, which assumes the sequence of sleep stages to be governed by the following property: the 
probability of transition from state m to state k at a certain time of the night depends only on the 
state of departure m and not on the entire past history of the states.  
Recently,  this  model  has  been  further  developed  including  multinomial  random  variables  for 
simultaneously characterizing all the possible transitions from a specific stage at a certain time. 
Multinomial  logistic  functions  have  been  then  introduced  for  describing  the  corresponding 
transition probabilities [2].  
The aim of this thesis is to evaluate whether the multinomial model proposed in [2] adequately 
describes the underlying system. Data from a clinical study conducted in patients with a diagnosis 
of primary insomnia are used for this analysis. 
Different diagnostic methods to investigate the adequacy and the performance of a categorical 
model are proposed and implemented in this thesis. I mainly focus my attention on those methods 
based  on  stochastic  simulations  considered  more  appropriate  for  categorical  type  of  data  as 
suggested in several papers in the literature [3, 4 ,5]. In addition, the model assessment includes 
also the evaluation of the estimation method adopted to identify multinomial model parameters. 
For this reason, I introduce in this thesis a diagnostic method derived by a recently proposed [6,7] 
approach for checking both model and estimation method performance. The key contribution of 
this work is to translate complex diagnostic methods based on simulations and statistics of re-
estimated parameters in a visual evaluation of the relevant model characteristics: in particular, the 
transition probabilities between sleep stages. This kind of visual comparison – applied for the first 
time in categorical models - has been called ‘Visual Estimation Check’ (VEC).  
This thesis is structured as follows: Chapter 1 provides some background on sleep physiology and 
its regulation mechanisms, including an overview on the instrumentation and the guidelines for 
assessing sleep stages. Chapter 2 describes different estimation methods, with particular emphasis 
on  the  population  approach,  adopted  in  our  analyses,  and  its  application  to  categorical  data. 
Chapter  3  presents  the  Markov-chain  model  used  for  describing  sleep  architecture,  including 
some details of the basic theory. Results are presented in Chapter 4 where the validation of the 
model and the outcome of the different diagnostic methods applied in this work are described. 
Finally, a critical discussion, also on possible further developments of this research project, is 7 
 
provided  in  the  Conclusions.  Code  implementing  models  using  a  non-linear  mixed  effect 
(NONMEM) approach and methods for validation analysis (in R) are reported in Appendix. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 . 
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Chapter 1 
Sleep: physiology fundamentals, 
treatment of insomnia and quantitative 
methods for its assessment 
   
 
 
Sleep is a complex, highly organized physiological process that is fundamental to life. It is a 
natural state of bodily rest characterized by total or partial unconsciousness and the inactivity of 
nearly all voluntary muscles. Both sensory and motor activities are suspended implying reduced 
response to stimuli and minimal movement. However, the responsiveness to endogenous and 
exogenous stimuli is not completely absent during sleep and the condition of unconsciousness is 
reversible.  
Sleep  is  not  a  homogeneous  state  of  unconsciousness  but  it  is  characterized  by  an  internal 
structure, called ‘sleep architecture’, defined by different stages and the transition between them. 
It has been demonstrated that the maintenance of such architecture is fundamental to determine 
sleep quality and, therefore, the physical and mental well-being.  
On the other hand, disorders in the natural pattern of sleep may lead to adverse consequences and 
may seriously affect patients’ health, productivity and life quality [8,9,10]. 
The prevalence of sleep disturbances indicates that it is a very common problem affecting both 
men and women, elderly and young population. The causes of sleep problems are different and 
often are related to other clinical pathologies. For these reasons, the appropriate diagnosis  and the 
treatment of sleep disorders is becoming more and more relevant.  
However, the purposes and mechanisms regulating sleep are not completely clear and the deep 
understanding of sleep architecture and patterns represents a great challenge to clinicians and 
pharmaceutical companies, that are leading an intense research in this field. 
The  first  attempt  to  describe  human  sleep  was  made  in  1930  by  Berger,  the  father  of 
electroencephalography  [11].  He  obtained  the  first  sleep  recording  and  noted  that  the  alpha 
rhythm disappeared when his subject fell asleep. A second important achievement was made in 
1937 when Loomis et al. [12] published the first continuous overnight EEG sleep recording in 
humans and proposed a scheme, the so called ‘sleep staging’, to summarize the EEG recording in . 
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a reduced dataset. They proposed a classification of the EEG activity recorded during sleep into 5 
stages: A, B,  C, D and E, on the basis of the predominant EEG rhythm in a fixed time domain. 
In 1953 Aserinsky and Kleitmain [13] discovered episodic electro-oculagraphic (EOG) activity 
occurring during sleep stage B every 90-120 minutes. Initially this activity was supposed to be an 
artifact  due to instrumentation,  but subsequent studies  demonstrated  that  these  episodes  were 
actually occurring. These events were called ‘Rapid Eye Movements’ (REMs). 
The authors tried also to establish the relation existing between REM stage and dreaming.  It was 
noted that dreaming happened in 20 of the 27 instances after the awakening from REM sleep 
stage. In 1957 Dement and Kleitman [14] suggested a new classification for sleep stages: sleep 
stages were divided into four Non-REM (NREM) stages and a REM stage. 
The next major improvement on sleep architecture description was made in 1959 when Jouvet 
[15] observed by the electromyography (EMG) technique muscular atonia related to the REM 
stage. He also introduced the concept that REM stage was a state in which the brain was ‘active’. 
The staging criteria were standardized in 1968, when Rechtschaffen and Kales developed and 
published ‘A Manual of Standardized Terminology, Techniques and Scoring System for Sleep 
Stages of Human Subjects’, [16], establishing the major rules for classifying sleep stages during a 
standardized sleep recording. This manual, generally reported as the ‘R & K Manual’, received a 
general consensus and became a gold standard in sleep measurements. In the ‘R & K Manual’, 
NREM sleep was divided into four stages (stages 1, 2, 3 , 4), with slow-wave sleep or deep sleep 
comprising stages 3 and 4 and, for contrast, light-sleep comprising stages 1 and 2. REM sleep was 
sometimes reported as stage 5. 
In 2004, the American Academy of Sleep Medicine (AASM) proposed several changes in the 
scoring system indicated by the ‘R & K standard’, the most significant being the combination of 
stages 3 and 4 into a unique stage, called Stage N3. These proposed changes were published in 
2007 in ‘The AASM Manual for the Scoring of Sleep and Associated Events’ [17].  
 
 
1.1.  Sleep stages 
 
Sleep stages and the other features related to sleep are commonly assessed by polysomnography 
in a specialized sleep laboratory. Polysomnography is a worldwide standardized procedure used 
for the diagnosis of sleep disorders. As a result of such a technique, it is possible (a) to recognize 
some important features/pathologies accompanying/affecting sleep (apneic episodes, restless leg 
syndrome, etc), (b) to exactly assess the sequence of sleep stages occurring during the night 
according  to  the  ‘Standard  manual’s  rules’  and  (c)  to  assess  some  important  aggregated 
parameters that help in quantifying the severity of the pathology under examination. 11 
 
 
1.1.1. Instrumentation: Polysomnography 
Plysomnography, abbreviated PSG, is a multi-channel tool that allows to simultaneously record 
relevant activities occurring during sleep. On the basis of these recorded parameters, the rules 
established by the ‘Standard manual’ permit to assess for each time interval of the night the 
corresponding sleep stage.  
A polysomnogram typically records a minimum of eleven channels requiring a minimum of 22 
wires attached to the patient. A computer system is used for recording, storing and displaying the 
data obtained by each channel. During sleep the computer monitor can display multiple channels 
continuously. In addition, sleep laboratories have video camera installed in the patient’s room in 
order to record also sleep-related behavioral features, as sleep-talking, snoring etc. 
The recording must be carried out with the least discomfort for the patient, hence it must be 
conducted in a quiet room similar to comfortable bedroom. Recording tools should be physically 
separated from the patient and wires and electrodes must disturb the patient as less as possible. 
Light and noises should be appropriately shielded. After the application of the electrodes and the 
calibration of the system, the lights should be turned off approximately at patient’s usual bed-
time. It should be taken note of any episode of snoring, sleep-vocalization or other activities 
occurring during sleep. In a standardized clinical study aimed to investigate any potential drug 
effect, the registration of the PSG measurement occurs during a predefined time interval (from the 
“light off” to the “light on” time that typically lasts 8 hours). 
Measurements include many recordings [18] listed below. 
 
•  EEG: Electroencephalography of brain waves   
The EEG remains the primary variable for staging the sleep. A single central channel is 
considered  sufficient for basic sleep staging. However, it is recommended to provide 
redundancy to permit adequate assessments of other EEG characteristics. Consequently, 
six or more channels of cortical activity are typically used, with electrodes preferentially 
attached to the scalp near the frontal (Fp1, Fp2), central (C3, C4) and occipital (O3, O4) 
portions of the brain.  
 
•  EOG: Electrooculography of eye movements 
Electrooculography  provides  important  information  regarding  sleep  onset  and  REM 
recognition. At least two electrodes are recommended: one positioned one centimetre 
above the outer canthus of the right eye and the other placed one centimetre below the 
outer canthus of the left eye.  
 . 
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•  EMG: Electromyography of skeletal muscle activity 
Submental  EMG  activity  is  used  to  determine  the  level  of  muscle  tone,  which 
significantly decreases during REM sleep. This channel is relevant   to determine both 
sleep  onset  and  REM  occurrence.  This  channel  also  provides  information  regarding 
patient movements. A single channel is considered enough: electrodes are placed under 
the chin, in the submental region. 
 
•  ECG: Electrocardiography of heart functions 
Electrocardiography allows to control heart functions during sleep. In fact, it can assess  
the severity of some cardiorespiratory disfunctions, such as in sleep apnea. A single ECG 
channel is sufficient for PSG recording. Typically, two electrodes are placed one in the 
sternal area and the other at a lateral chest location. 
  
•  Respiratory Effort and Airflow 
The monitoring of respiration during PSG is necessary for the detection of apneas and 
hypopneas. It is important to record at least 2 key parameters: (a) air exchange through 
both  the  mouth  and  nose;  (b)  expansion  and  relaxation  of  the  thorax  and  abdomen 
indicating respiratory effort. 
Air exchange can be measured by using different types of transducers. The measurement 
of  the  expansion  and  relaxation  of  thorax  and  abdomen  may  be  accomplished  by 
measuring  intercostal  EMG  and  thoracic/abdominal  impedance  or  using  strain  gauge 
devices. Respiratory pauses are considered apneic episodes when persist at least 10 sec. 
The absence of respiratory effort and, consequently, of airflow indicates the presence of a 
‘central apnea’, while the presence of respiratory effort without air exchange represents 
an  ‘obstructive apnea’. Oxygen saturation may drop significantly, usually in a direct 
relationship with the lengths of apneas. 
 
•  Blood Oxygenation (    or    saturation) 
The  measurement  of  blood  oxygen  in  the  PSG  system  facilitates  detecting  apneas 
episodes and other respiratory difficulties. Monitoring of blood oxygenation indicates the 
severity  of  breathing  disfunctions.  Pulse  oxymetry,  a  noninvasive  technique,  is 
recommended. The sensors of this tool can be easily attached to the patient’s fingertips or 
earlobs and can also be easily interfaced with polygraphic recorder. It is also possible to 
measure transcutaneous P   using a Clark oxygen electrode attached directly to the skin.  
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•  Expired     
Quantifying  expired  amount  of CO  is  another  useful  tool  for  monitoring  respiratory 
functions. During expiration, the partial pressure of CO  approximates the intra-alveolar 
P    and this type of information can be considered as a marker of air exchange enabling 
the evaluation of some respiratory pathologies, as pulmonary disease, that modify the 
respiratory variables. 
A small diameter tube connecting the instrumentation to patient’s mouth or nostrils is 
often used to  measure air flow. 
 
•  Body/Limb Movements 
Some sleep disturbances are caused by the restless legs syndrome (RLS) or the periodic 
myoclonus in sleep (PMS). These pathologies imply movements compromising a good 
sleep. These movements are easily detectable in a sleep laboratory videotaping the patient 
or measuring muscular activity by means of EMG or accelerometers. 
 
•  Behavioral Observation 
An integral part of PSG procedure is the observation of patient’s behavior, noting any 
vocalization  or  snoring  during  sleep.  This  is  easily  implemented  through  a  system 
composed by a video-camera, a microphone and a monitor carefully observed by the 
assigned technician.  
 
 
Figure 1.1: Typical polysomnographic installation.  . 
 
14             
 
In addition to recorded trace, the results of sleep monitoring procedure are typically reported with 
few  additional  information:  (a)  patient’s  information  for  his/her  identification;  (b)  patient’s 
history, including any existing pathology and relevant drugs assumed in the preceding 30 days; 
(c)  recording  conditions,  including  beginning  and  ending  time  of  recording,  list  of  recorded 
channels (each being labeled), and, when relevant,  anatomic location of sensors; (d) a summary 
of polygraphic characteristics such as sleep statistics (aggregated parameters as sleep latency, 
total sleep time, etc), respiratory characteristics (presence/absence of snoring, number of apneic 
episodes,  etc),  heart  rate  values,  movements  (frequency  of  occurrence,  etc),  behavioral 
observations, EEG characteristics (basic characterization of the awake and sleep patterns and a 
description of any other feature). 
The  ‘Standard  manual’  provides  the  rules  for  staging  the  sleep  according  to  the  obtained 
physiological parameters of interest. Night time, that is the recording time, is divided into 30-
second intervals and  the corresponding sleep stage is assessed for each interval, in an automatic 
computer-based way according to those rules. 
 
1.1.2. Stage classification 
The first step in the automatic sleep analysis is signals pre-processing. This step is necessary to 
reduce the enormous amount of raw data and remove artefacts affecting signals. This allows 
automatic statistical tools to analyze the data. As a result of this process, it is possible to clearly 
distinguish specific features necessary to discriminate sleep stages as follows: 
 
•  EEG: it is possible to recognize the amplitude and power of regular waves (beta, alpha, 
theta  and  delta  waves)  and  specific  patterns  overlapped  to  the  basic  rhythm:  K-
complexes, sleep spindles, and vertex sharp waves. 
K-complexes are specific waveforms occurring during sleep and distinguishing a specific 
sleep  stage  (stage  2).  They  are  characterized  by  a  brief  negative  high-voltage  peak, 
usually greater than 100 µV, followed by a slower positive complex at around 350 to 550 
ms  and  a  final  negative  peak  at  900  ms.  K-complexes  occur  spontaneously  or  as  a 
response to exogenous or endogenous stimuli. A sleep spindle is a burst of brain activity 
visible on an EEG. It consists of 12-16 Hz waves that occur for 0.5 to 1.5 seconds. Vertex 
sharp waves are particular waveforms occurring during sleep but not characterizing any 
single stage. Their amplitude is 50-150 µV. 
  
Figure 1.2: EEG specific feature
•  EOG: the specific patterns are rapid eye movements and slow eye movements which have 
to be distinguished from each 
 
The second step is the combination of these extracted features and waveforms in order to assess 
the correct sleep stage. The ‘
categorized as AWAKE (A
criteria. 
 
•  AWAKE (AW)  
(a)  EEG:  Wakefulness  with  eyes  closed  is  characterized  by  an  EEG  rhythm 
predominantly in the alpha range (
a significant mental task diminishes or block
determined when alpha activity decreases to duration of less than 50% of an epoch or 
when a sleep spindle, K
wakefulness is scored.
(b) EMG: Moderately muscle activ
(c)  EOG: Eye movements may occur, both rapid and slow
 
 
Figure 1.3
 
 
EEG specific feature that help in assessing sleep stages: K-complex and Sleep Spindle.
 
EOG: the specific patterns are rapid eye movements and slow eye movements which have 
to be distinguished from each other. 
The second step is the combination of these extracted features and waveforms in order to assess 
the correct sleep stage. The ‘Standard manual’ establishes that each 30-second interval should be 
AW) or sleep stage 1, 2, 3, 4 or REM, according to the following 
EEG:  Wakefulness  with  eyes  closed  is  characterized  by  an  EEG  rhythm 
predominantly in the alpha range (from 8 Hz to 12 Hz). Opening the eyes or engaging 
a significant mental task diminishes or blocks alpha activity. Sleep onset epoch is 
determined when alpha activity decreases to duration of less than 50% of an epoch or 
when a sleep spindle, K-complex, vertex wave or theta activity occurs; otherwise 
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.3: Typical EEG, EOG and EMG activities related to the AWAKE state.
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•  STAGE 1 (ST1) 
(a)  EEG: Stage 1 marks the transition from alpha waves to theta waves (ranging from 4 
Hz to 7 Hz). This sleep stage is transitional and does not last long. Often this state is 
not perceived as sleep when a person is asked; it is also referred to as ‘somnolence or 
drowsy sleep’. There are no K-complexes or spindles. 
(b) EMG: Loss of some muscle tone. 
(c)  EOG: Slow eye movements. 
 
 
 
Figure 1.4: Typical EEG, EOG and EMG activities related to STAGE 1 sleep. 
 
 
•  STAGE 2 (ST2) 
(a)  EEG: Stage 2 is characterized by the presence of sleep spindles and K-complexes 
overlapping on a theta range EEG rhythm. Both patterns are clearly recognizable 
from the background activity.  
(b) EMG: Muscle tone is slightly lower than during stage 1 sleep. 
(c)  EOG: Usually there are no more eye movements. 
 
 
 
Figure 1.5: Typical EEG, EOG and EMG activities related to STAGE 2 sleep. 
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•  STAGE 3 (ST3) 
(a)  EEG: Stage 3 is designated when there is 20% to 50% of high amplitude (more than 
75 µV ) delta activity in an epoch. 
(b) EMG: Muscle tone is much lower. 
(c)  EOG: No eye movements. 
 
 
 
Figure 1.6: Typical EEG, EOG and EMG activities related to STAGE 3 sleep. 
 
 
•  STAGE 4 (ST4) 
(a)  EEG: Stage 4 is scored when high amplitude delta activity covers more than 50% of 
an epoch. To awake a person from stage 3 or stage 4 is very difficult and usually it 
takes a few minutes to regain full consciousness. They are also called ‘slow-wave 
sleep’ or ‘deep sleep’. Slow wave sleep has a restorative function, resulting more 
copious after physical works or sleep deprivation.  
(b) EMG: Muscle tone is much lower. 
(c)  EOG: No eye movements. 
 
 
 
Figure 1.7: Typical EEG, EOG and EMG activities related to STAGE 4 sleep. . 
 
18             
 
•  REM (REM) 
(a)  EEG: During REM sleep the EEG shows mixed frequencies (theta and alpha range). 
Saw-tooth theta waves may occur. REM sleep may be split into 2 different phases: 
periods  when  eye  movement activity  is high,  and  period  when  REM  background 
activity continues without phasic activity. These two phases are called ‘phasic REM 
activity’ and ‘tonic REM activity’. REM stage is often accompanied by dreaming 
activity  [13].  The  particular  EEG  recorded  during  REM  indicates  high  cerebral 
activity. This high cerebral activity has been confirmed by cerebral blood flow during 
REM activity measured with positron emission tomography technique.  
(b) EMG: Muscle tone is the lowest, presumably to protect from possible self-damage 
caused as a consequence of dreaming activity. 
(c)  EOG: Rapid eye movements 
 
 
 
 
 
Figure 1.8: Typical EEG, EOG and EMG activities related to Tonic REM sleep and Phasic REM sleep. 
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1.1.3. Sleep statistics  
Some  important  characteristics  of  sleep  can  be  derived  from  plysomnographic  data.  Such 
characteristics are in the clinical practice used for quantifying both the severity of sleep disorders 
and hypnotics efficiency. These parameters are also called ‘aggregated parameters’ because they 
reflect the overall trend of sleep during the night. The following definitions of sleep parameters 
are listed for reference: 
-  Total recording time (TRT): the duration of time from the start to the end of a recording, 
usually 8 hours. 
-  Time in bed (TIB): the duration of time from ‘light off’ to final awakening. 
-  Sleep onset (SO): the first epoch followed by 19 epochs of ‘non awake’ stages. 
-  Sleep period time (SPT): the duration of time from SO to final awakening. 
-  Latency to persistent sleep (LPS): the duration of time from ‘light off’ to SO. 
-  Wake after sleep onset (WASO): the total time spent awake during SPT. 
-  Total sleep time (TST): the amount of actual sleep time in a recording. 
-  Sleep efficiency (SE): the ratio of total sleep time to time in bed, i.e. TST/TIB*100. 
-  Time spent in each of the sleep stages (tAW, tST1, tST2, tST3, tST4, tREM). 
-  Number of transition to each stage (nAW, nST1, nST2, nST3, nST4, nREM). 
-  Mean  extension  of  each  stage  (meanAW,  meanST1,  meanST2,  meanST3,  meanST4, 
meanREM). 
 
1.1.4. Normal Sleep Pattern 
The sequence of sleep stages across the night is called ‘sleep architecture’ and usually follows a 
particular structure made by repeated ‘sleep cycles’ of alternated REM and Non-REM sleep, each 
lasting approximately 90-120 minutes. These cycles are repeated three to six times each night. 
Sleep stage 2 is the predominant stage, covering more than half of the night, and REM stage 
counting for another 20% to 25%. Stage 1 sleep is a transitional state, consequently it covers a 
minimal part of the night, approximately 1% to 5%, essentially in the phase of sleep onset and in 
the transition to light sleep. Slow wave sleep predominates the first third of the night, while REM 
sleep predominates in the last half of the night.  
Spontaneous arousals and brief awakenings are common during or after REM sleep. Awakenings 
are defined as prolonged arousals implying cardiovascular activation [19,20,21].  
Total duration of sleep varies from 7.5 and 8.5 hours in the majority of healthy persons. Mental 
and  physical  tasks  preceding  sleep  time  seriously  influence  sleep  architecture:  physical  work 
increases deep-sleep, while mental work increases REM sleep percentages.  
As mentioned above, the maintenance of such pattern is fundamental to preserve sleep quality. 
 . 
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Figure 1.9: Normal sleep pattern. On the left a normal sequence of sleep stages during the night. On the right 
a diagram showing the total time spent in each stage. 
 
 
 
1.2.  Mechanisms regulating sleep 
 
Maintaining  a  dynamic  balance  between  wakefulness  and  sleep  is  necessary  to  preserve  the 
overall wellness and restore mental and physical capabilities. The mechanisms regulating this 
balance are not completely known but many papers in literature [20,22] suggest that three key 
drives influence this process: (a) the autonomic nervous system, (b) the homeostatic system, (c) 
the circadian rhythm. These mechanisms are independent but clearly are involved to coordinate 
the sleep and wakefulness periodicity, allowing for adaptation to sudden circumstances provoking 
shifts in the time and duration of sleep.  
 
1.2.1. Autonomic nervous system 
In general, a drop in the sympathetic activation accompanied by a simultaneous increase of the 
parasympathetic activity favourites sleep. Consequently, anything, exogenous or endogenous, that 
increases  sympathetic  outflow  can  disturb  sleep.  For  example,  assuming  caffeine  or  nicotine 
(exogenous)  or  being  in  particular  states  of  anxiety  (endogenous)  are  well  known  factors  to 
disturb sleep.  
During stressful periods, increased sympathetic activation results in higher levels of cortisol and 
adrenocorticotrophic  hormone  which  increase  wakefulness  and  inhibit  restorative  slow-wave 
sleep resulting in a ‘unrestorative’ sleep.  21 
 
The autonomic mechanism is responsible of a ‘survival function’ in case of necessity during the 
night: it promotes quick response and sustained alertness. However, when this mechanism does 
not properly work, it may contribute to sleep disturbances.  
 
1.2.2. Homeostatic control 
The homeostatic process is determined by the amount of sleep and wakefulness. It has been 
demonstrated that the longer the sleep deprivation lasts the stronger the need to sleep becomes. 
Many sleep-deprivation studies have been conducted to determine the effects produced by sleep 
loss: sleep deprivation negatively affects attention, cognitive abilities and behavioural attitudes, 
entailing irritability and more easily (potential) demoralization. 
Reduction  of  sleep  time  the  previous  night  linearly  increases  the  speed  of  falling  asleep  the 
following day: this can be quantified using a standardized measure of daytime sleepiness: the 
Multiple Sleep Latency Test (MSLT) [23].  
Since  the  slow-wave  sleep  has  a  fundamental  restorative  function,  partial  or  total  sleep 
deprivation increases the amount of slow wave sleep rate during recovery sleep [19,22]. 
Physiologically,  sleep  deprivation  results  in  increased  cortisol  levels,  thyroid  activity  and 
catecholamine turnover [24,25]. 
 
1.2.3. Circadian rhythm 
Independently  of  the  homeostatic  process,  a  circadian  process  influences    the  sleep-wake 
alternation according to the 24-hours light-dark cycle. The Central Nervous System CNS area 
involved with this mechanism is the suprachiasmatic nucleus (SCN), which is considered to be a 
biological  clock.  SCN  controls  a  variety  of  biological  functions,  including  the  core  body 
temperature. For this reason, the core body temperature is often used as a monitoring marker for 
circadian clock’s period, phase and amplitude.   
In general, in humans, the body temperature is characterized by: 
•  a nadir early in the morning (between 3 AM and 5 AM) 
•  a peak in the early evening (between 5 PM and 8 PM) 
•  a decline after midday (between 1 PM and 3 PM)  
 
It has been demonstrated [26,27] that, according to this rhythm: 
•  maximum sleepiness occurs when body temperature reaches nadir 
•  maximum alertness occurs at body temperature peak 
•  drowsiness appears when temperature starts to fall 
 . 
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A variety of hormonal and metabolic functions are strictly related to the circadian process: blood 
levels of cortisol, prolactin, growth hormone, thyroid stimulating hormone and melatonin are 
driven by this daily clock.  
 
 
1.3.  Functions related to sleep  
 
In addition to obvious physical and mental restorative functions, it is possible to attribute to sleep 
two further roles: (a) the capability to restore/maintain the immunologic system and (b) memory 
consolidation.  
It has been demonstrated, in fact, that a low quality sleep or sleep deprivation seriously affects the 
immune system. For example, in [28] the authors proved that a group of 24-hour sleep-deprived 
rats had a 20% decrease in white blood cell count, compared with a control group. 
It  is  also  well  demonstrated  that  sleep  deprivation  negatively  affect  memory  functions, 
compromising cognitive tasks as decision making, reasoning, etc [29].   
 
1.3.1.  Memory and learning 
A variety of studies have tried to clarify the relationship existing between sleep and memory 
consolidation.  The  mechanisms  involved  in  the  memory  process  consist  of  brain  structure’s 
reorganization  into  new  neuronal  connections  on  the  basis  of  nerve  cell  dendrites’ 
information/stimuli. This process needs to be fulfilled during the absence of continuous stimuli 
and this is the likely reason  for which memory consolidation is accomplished during sleep. 
There are essentially two types of learning and associated memory.  
 
•  The ‘declarative memory’ which is tested through a series of pairs of related terms, such 
as  hand-glove,  leaf-tree  etc.  This  type  of  memory  is  involved  in  learning  foreign 
languages.  
 
•   The ‘procedural memory’ which is tested through the learning of mirror-writing. This 
test consists on writing some sentences while the writing-hand is hidden being helped by 
a mirror only. Procedural memory is necessary for all types of task involving movements 
learning, such as car driving, skiing, etc. 
 
Several studies have shown that not only REM sleep, but also NREM sleep is important for 
memory functions. In particular, in [30] it has been demonstrated that memory is influenced 23 
 
differentially by certain sleep stages: subjects tested in the early night, in which slow wave sleep 
activity is prevalent, demonstrated a better declarative memory with respect to a control group, 
while subjects tested at the end of the night, when REM sleep is prevalent, performed better in the 
procedural memory test. This implies that improvements of declarative memory can be attributed 
to NREM sleep (SWS in particular) while those of procedural memory to REM sleep.  
 
 
1.4.  Sleep disorders 
 
As mentioned above, disruptions in the correct maintenance of sleep architecture and sleep-wake 
balance may lead to serious consequences for individuals and society in general, compromising 
both productivity and wellness. 
Sleep disorders are very common complaints affecting a large segment of world’s population. The 
prevalence of such disorders is estimated to be approximately the 10% [31,32].  
Sleep disorders consequences represent a substantial economic burden and, for this reason, it is a 
major objective for clinicians properly diagnosing and treating this kind of pathology.  
The guidelines for diagnosing sleep disorders are listed in the ‘Diagnostic and Statistical Manual 
of Mental Disorders-Fourth Edition-Text Revision’ (DSM-IV-TR) [33].  
Pharmaceutical companies have invested a lot of resources to develop new hypnotic drugs with a 
more safe and effective profile for the treatment of insomnia.  
 
1.4.1.  Classification/Definitions 
According to the ‘Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition-Text 
Revision’ (DSM-IV-TR) [33], sleep disorders can be divided into two main categories.  
 
•  ‘Insomnia’: defined as difficulty in falling asleep (sleep onset), difficulty in staying asleep 
(sleep maintenance) or low quality of sleep (non-restorative sleep). These symptoms may 
occur  simultaneously  or  affect  differentially  some  individuals,  causing  for  example 
exclusively early morning awakenings.  
Duration of insomnia can be transient (from 1 to several nights), short term (from several 
days  to  a  month)  or  chronic  (lasting  for  months  or  years).  Transient  and  short  term 
insomnia often may be caused by changes in the sleep environment or by acute stressful 
experiences. Chronic insomnia, instead, may be of primary nature or secondary to other 
conditions/pathologies. When insomnia is secondary to another pathology, often it is not . 
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possible  to  establish  whether  insomnia  is  the  cause  or  the  effect,  but  any  specific 
treatment should take into account the coexistence of these pathologies.  
There  are  six  major  categories  in  which  chronic  insomnia  can  be  classified:  medical 
(related to medical diseases), psychiatric (following or preceding psychiatric disorders), 
circadian  (disordered  circadian  rhythm),  behavioural,  pharmacologic  (due  to  drugs’ 
undesired effects) and primary (not conditioned, independent disorder).   
Transient and chronic insomnia obviously entail different therapeutic approaches. One of 
the most important objective in treating transient insomnia is to prevent its evolution to 
chronic insomnia.  
Furthermore, it emerges from several studies [31,32] that risk factors exist for chronic 
insomnia, such as age, gender, medical disease, psychiatric disease and shift work. 
 
•  ‘Disorders  associated  with  excessive  sleepiness’,  for  example  narcolepsy:  these  are 
chronic  sleep  disorders  characterized  by  excessive  daytime  sleepiness  (EDS)  which 
involves extreme daytime fatigue and that may lead to fall asleep at inappropriate times. 
Narcoleptics usually experience disturbed nocturnal sleep and an abnormal daytime sleep 
pattern, which is often confused with insomnia.  
 
1.4.2.  Consequences of insomnia 
Consequences  associated  to  transient  or  short  term  insomnia  are  similar  to  those  already 
highlighted about sleep deprivation studies: there is an increase in daytime sleepiness and an 
impairment of psychomotor function. Daytime sleepiness can be quantified using the MSL test, 
while psychomotor impairment can be assessed by performing different psychomotor tests, such 
as  reaction  time  test,  vigilance  test  etc.  Furthermore,  transient/short  term  insomnia  affect 
significantly the ability of sustain attention, resulting in increased daytime lapses, that are periods 
of lack of responsivity (most likely effects of  the so called ‘microsleep’). 
Chronic insomnia is more complex and its consequences vary significantly from case to case. 
Some  of  the  consequences  attributable  to  chronic  insomnia  may  be  daytime  fatigue  and 
sleepiness,  as  in  the  case  of  rheumatoid  arthritis  and  other  medical  diseases  provoking 
fragmentation of sleep. However, in most cases people suffering of chronic insomnia do not show 
daytime sleepiness, but rather a greater alertness as shown by the higher mean latency in MSL test 
when compared to a control group without insomnia. 
Many  papers  in  literature  [34,35]  have  also  shown  that  often  insomnia  is  a  precursor  for 
depression, reducing subject’s quality of life. 
It  has  been  demonstrated  that  consequences  of  insomnia  for  the  society  in  general  are 
economically relevant. People affected by this pathology are more likely to absenteeism and have 25 
 
higher rates of accidents, decreased productivity and quality of life [32]. Direct costs, those of 
medical care, have been estimated to be around $14 billion [36]. There are also relevant indirect 
costs due to decreased economic output attributable to insomnia; these have been quantified in 
around $100 billion [37]. 
 
1.4.3.  Treatment of insomnia  
In our culture, there is the tendency to not consider insomnia as a true medical disease, but rather 
as  a  minor  problem,  and  people  often  do  not report  their  sleeping  difficulties  to  the  general 
practitioner. There is also a general concern about long term use of hypnotic drugs, regarding in 
particular  potential  addiction  and  abuse  liability.  Some  physicians,  in  fact,  are  reluctant  to 
prescribe hypnotic drugs because they are considered symptomatic drugs without solving the real 
causes of insomnia. 
However, physicians are now more experienced in treating such problems and are now available 
new hypnotic agents more safety and effective.   
The purpose of insomnia treatment is obviously to improve patient’s quality of life. In doing so, it 
is necessary to identify and remove any existing problem that may cause insomnia. This goal may 
be achieved through an appropriate treatment consisting in pharmacologic therapy combined to 
educational and behavioural approaches.  
In the past, bromides, barbiturates, paraldehyde and methaqualone have been used as hypnotics, 
but although they have proved sedating properties, they also have significant toxicity problems. 
For this reason, their use is no more recommended. Current hypnotic drugs indicated in treating 
insomnia include traditional benzodiazepines and non-benzodiazepines. The non-benzodiazepines 
are positive allosteric modulators of the GABA-A receptor. Like the benzodiazepines, they exert 
their effects by binding to and activating the benzodiazepine site of the receptor complex.  
 
•  Traditional  benzodiazepines  have  been  available  since  the  1960s.  These  types  of 
medications vary significantly in their elimination half-lives and subsequent duration of 
action.  The  half-life  times  range  from  few  hours  to  few  days,  and  this  is  the  major 
concern about their use. The longer half-life time, in fact, may have daytime undesired 
effects after drug’s intake, compromising daytime impairment and increasing the risk of 
accidents and falls. Among the benzodiazepines approved for the treatment of insomnia, 
the fast acting ones with short half-lives such as estazolam, triazolam, and temazepam are 
recommended.  Longer-acting  benzodiazepines  such as  nitrazepam  and  diazepam  have 
residual effects that may persist into the next day and are, in general, not recommended.  
 . 
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•  Newer nonbenzodiazepines, (zolpidem and zaleplon, zopiclone, eszopiclone) are available 
since 1990s. These medications have a shorter half-life time (1-2 hours), so there is a very 
little risk of morning residual effect. Their action implies a rapid sleep onset, so the 
patient can take them just before going to bed. Serious adverse reactions are infrequent. 
The short term safety and efficacy of these new hypnotics have been well proved [38,39] 
and clinical experience supports safety in long-term intermittent use. Continuous long 
term use is not recommended as tolerance, dependence and addiction can occur. 
 
Hypnotics’ efficacy, as already mentioned, is generally determined on the basis of the effect they 
exert on the aggregated parameters. Hypnotic medications currently in use are demonstrated to 
positively influence the Latency to Persistent Sleep (LPS), inducing a rapid sleep onset [38,40]. 
Integrated to the pharmacologic approach, it is of relevant importance the evaluation of specific 
behaviours  and  circumstances  that  favourite  insomnia.  For  this  reason it  is  indispensable the 
continuous monitoring and the constant support of the patient. 
 
 
1.5.  Aim of this work 
 
Sleep  disorders  are commonly  assessed through  ‘polysomnography’,  a  quantitative  diagnostic 
technique  that  consists  in  the  simultaneous  recording  of  the  principal  electrophysiological 
activities involved in the sleep process.  
Currently,  the  clinical  use  of  polysomnography  is  mainly  related  to  assess  sleep  aggregated 
characteristics (WASO, LPS, etc.). However, averaging  PSG data into these  parameters implies 
a substantial loss of information regarding the sleep architecture considered as a time-course 
pattern  among  specific  sleep  stages.  The  maintenance  of  this  internal  structure  has  been 
demonstrated to be of significant importance.  
A  Multinomial  Mixed-Effect  Markov-chain  model  has  been  recently  proposed  to  properly 
describe the sleep architecture.   
The aim of the work presented in this thesis is to assess the appropriateness of this Markov-chain 
model,  evaluating  whether  the  proposed  model  adequately  describes  the  underlying  system, 
provides precise predictions for the parameters of interest and avoids biased estimates. 
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Chapter 2 
Model identification methods  
   
 
 
2.1.  Introduction 
 
As described in the previous chapter, the main objective of this thesis is to evaluate a recent 
multinomial proposed for analyzing polisomnography data [2]. However, bias and imprecision in 
the model estimations and predictions may depend not only on possible model misspecifications 
but also on weaknesses in the estimation methods. When dealing with data from clinical studies 
the key objectives of any modeling analysis is to establish both population mean and individual 
responses,  since  the  drug  under  development  has  to  be  effective  and  safe  for  the  whole 
population. 
Let the gathered data arise from M subjects participating in a certain clinical study and let X be the 
data matrix, where each row contains individual data on N different times: 
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Suppose such data need to be described through a mathematical model. Classical approaches, e.g. 
Least  Squares  (LS),  Weighted  Least  Squares  (WLS),  Maximum  Likelihood  (ML)  estimate, 
Bayesian approach, etc., are generally designed for individual fitting: 
 
   =      ,    +   , 
 
where     are  the  individual  data,      the  corresponding  model  prediction,  z  the  independent 
variable,    the individual parameters and    the vector of the random error affecting individual 
data. The random error is generally due to measurement errors and noise and it is supposed to be 
drawn  from  a  Gaussian  distribution  with  zero  mean  and  covariance  matrix  equal  to  Σ, 
  ~  0,  .  . 
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These approaches present some identification problems in case of noisy or sparse individual data: 
individual estimates in certain cases may be not accurate or impossible to obtain. Furthermore, 
information at the mean and individual levels are often needed. Consequently, when working in 
similar contexts, it is suitable to build models and identify the corresponding parameters using the 
so called ‘population approaches’.  
Let the individual parameters of the population under examination belong to a certain distribution 
(gaussian, lognormal, etc.), characterized by mean   and covariance Ω: 
 
   ~       ,Ω . 
 
It is then possible to think that individual data are realizations of such distribution. The population 
approach allows to investigate, with varying levels of precision, both the mean parameter and the 
variability in the population, i.e. the first two moments of the parameters distribution,   =   ,Ω . 
In this chapter, population approaches are illustrated in detail with particular emphasis on the 
‘mixed-effect modelling approach’ and its application in the case of categorical data.  
 
 
2.2.  Naїve average data approach 
 
When clinical studies are performed with the same drug administration and sampling schedules 
for all the subjects in a population, the simplest method for analyzing data is to use a ‘Naїve 
Average Data’ (NAD) approach, which allows to obtain an estimate,    , of the mean population 
parameter, θ. 
This approach consists in: 
(a)  computing the average value of the data for each sampling time:  
 
    =
1
 
    
 
   
,          = 1,...,  
 
where t indicates the sample number, i the subject number, N the total number of sampling         
times and M the total number of subjects (the resulting mean vector is      = [   ,   ,…,   ]); 
 
(b) fitting a model to the mean data vector:     =    ,     +  . 
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This approach is very easily implementable, but it is rather poor in terms of performance and it 
can be very misleading (i.e., leading to wrong models). Imagine, for example, to have gathered 
data which can be described with a mono-exponential decay law:  
 
   =       −     +   . 
 
The mean curve used by NAD approach seems to exhibit a bi-exponential decay, as shown in 
Figure 2.1. That is, data averaging produces a distorted picture of the underlying model. 
 
 
Figure 2.1: Naïve average data approach applied to mono-exponential data. Figure obtained from ‘Models and control 
of Biological Systems 2’ course 2007-2008. 
 
Furthermore,  such  approach  cannot  provide  any  information  on  the  individual  behaviour:  all 
sources of variability disappear with the computation of the mean response.  
 
 
2.3.  Naїve pooled data approach 
 
The ‘Naїve Pooled Data’ (NPD) method was proposed by Sheiner and Beal in [41]. Unlike the 
NAD approach, the NPD approach is far more general: it considers all data as belonging to one 
unique individual. The subscript i disappears and the subscript t indexes all the available (z, x) 
pairs:  
 
   =     ,      +   , 
 . 
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where f is the model prediction for the ‘reference subject’. The latter is characterized by a set of 
parameters,      ,  which  can  be  estimated  using,  for  example,  the  LS  method,  where  the 
following global ‘objective function’ (OF) is minimized: 
 
         =        −     ,        
 
   
 
   
. 
 
The resulting value is therefore an estimate of the mean population parameters,    .  
This approach performs well in case of small variations between subjects but cannot provide any 
information on the individual behaviour: all sources of variability are confounded together.   
 
 
2.4.  Standard two-stage approach 
 
The ‘Standard Two-Stage’ (STS) approach consists in: 
(a)  estimating individual parameters,   , by individually fitting each subject data (through for 
example a classical ML approach or a WLS method as in the following formula): 
 
     =         [   −      ,    ]    [   −      ,   ], 
 
where   is the covariance matrix of the residual errors; 
(b) computing population mean and covariance as empirical mean and covariance on the     , 
as follows: 
    =
1
 
     
 
   
, 
Ω   =
1
 
       −           −     
 
 
   
, 
where     and Ω   are the estimated  population mean and covariance, respectively.  
The advantage of the STS approach is its simplicity, but the STS estimator is demonstrated to be 
polarized. Ideally, it would be suitable to estimate the true population variability only, by using 
the true individual residuals,   : 
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Ω =  [    
 ] =
1
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 , 
where   
∗, ∗ are  the  true  individual  and  mean  parameters.  But  using  the  STS  approach  the 
individual residuals are instead: 
 
   =       −      =      −   
∗ +   
∗ −  ∗ +  ∗ −     
 
                                                 Error on the                  Population                Error on the   
                                             individual estimate           variability              mean estimation 
 
 
Moreover,  population  parameters  are  obtained  in  a  second  step,  non  influencing  individual 
estimates. For this reason, individual estimates are not improved with respect to the estimates 
obtained with the traditional approaches. Furthermore, individual fitting in the first step needs 
‘rich data’ to be correctly performed, otherwise it tends to over-estimate parameters dispersion. 
 
 
2.5.  Iterative two-stage approach 
 
The ‘Iterative Two-Stage’ (ITS) approach is an iterative method which consists in the following 
steps. 
 
(a)  Individual parameters,   , are estimated by individually fitting each subject data. 
(b) Population mean and covariance are computed as empirical mean and covariance, as in 
the STS approach,        and Ω     . 
(c)         and Ω      are used as initial estimates for     and Ω  :        =       ,   Ω      = Ω     . 
(d) Individual parameters at k-th iteration,     
   , are estimated with a Bayesian approach, 
for example a MAP approach, using as prior for the estimands the parameters obtained 
at the previous iteration: 
 
    
    =         [   −      ,   ]    [   −      ,   ] + 
+[   −         ] {Ω       }      −          . 
 
(e)  Individual parameters obtained at the previous step are therefore used to re-estimate 
population parameters,       ,  Ω     , where k indicates the number of iterations: 
 . 
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(f)  Steps (d) and (e) are repeated until convergence. 
 
This method allows the estimation of the population parameters,   and Ω, to be estimated. It also 
provides  individual  parameter  values,  estimated  using  information  derived  not  only  from 
individual data but also from population parameters distribution (priors). However, ITS method, 
being an iterative method, involves a certain computational burden and may produce polarized 
estimates when the number of iterations is excessive.   
 
 
2.6.  Non-linear mixed-effect approach: theory 
 
The ‘Non-linear Mixed-Effect’ (NLME) approach is one of the most interesting for population 
analysis,  and  it  is  particularly  well  suited  for  biological  and  medical  data,  which  display 
heterogeneity of responses to stimuli and treatments. This approach is based on the assumption 
that  the  (unknown)  process  to  be  described is  characterized  by  a  typical  behaviour  which  is 
common to the whole population and by some sources of variability that make the individual 
behaviours differ from the typical one. The latter is determined by the so called ‘fixed effects’, 
while  the  identified  sources  of  variability  are  of  two  different  types  and  are  called  ‘random 
effects’. The first source of variability is the intrinsic difference that exists among subjects: one 
individual is obviously different from another one. This is called ‘inter-individual’ or ‘between 
subject’ variability. Mostly in the medical field, to understand the variability between subjects is 
as important as to understand the characteristics of the typical individual. The second source of 
variability  is  the  ‘residual  error’  (also  called  ‘noise  or  ‘intra-individual  error’):  this  is  the 
difference  between  the  prediction  of  the  model  for  the  individual  and  individual  measured 
observations. It is also called ‘intra-individual’ or ‘within subject’ variability. For taking into 
account all of these assumptions, the mixed-effect approach specifies the model in a hierarchical 
fashion,  integrating  an  ‘individual’  model  and  a  ‘population’  one.  In  this  way,  it  allows  to 
estimate both the vector of population characteristics,   =   , Ω , and the individual parameters, 
  . 
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Individual model  
The individual model is aimed to describe individual data specifying the relationship between the 
dependent variables, independent variables and individual parameters.  
Let 
            be the independent variable, for example ‘time’ in a time series; 
            be the t-th value of the independent variable, t = 1, …, N; 
            be the t-th observation of the i-th individual, t = 1, …, N and i = 1, …, M; 
            be the vector of model parameters of subject i.  
 
Each individual measure,    , can be described by the individual model in this way: 
 
    =       ,    +    ,     ∀  = 1,…, , 
 
where       ,    is the individual model prediction and     is the residual error.  
Using a vector notation: 
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Classical assumptions for the residual errors    , or  are that they 
(a)  have zero mean, 
(b) are uncorrelated, 
(c)  are normally distributed. 
 
Therefore,      are independently normally distributed with 
 
 [  |  ] = 0, 
      |    =      ,  , 
 
where    is a diagonal matrix depending on   (a constant characteristic across individuals) and 
possibly on the individual parameters (according to the error model structure). In practice,  
 
  ~  0,     ,   . 
 
 . 
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Population model  
A model for    is also needed in order to account for inter-individual variability among the   . In 
particular, the population model relates the individual parameters to the covariate vector, the fixed 
effects and the inter-individual random effects.  
Let 
      be the covariate vector, i.e. the set of individual values for weight, age, etc., 
      be the vector of inter-individual random effects associated with the subject i, 
      be the vector of fixed effects. 
 
A general population model is given by 
 
   =    ,  ,   , 
 
where   is  a  multi-dimensional  function,  and     are  supposed  to  be  drawn  from  a  normal 
distribution having zero mean and Ω covariance matrix, i.e. 
 
  ~  0,Ω . 
 
Eventually, the model can be expressed as follows: 
 
   =      ,   ,  ,     +   ,      ~  0,Ω ,       ~  0,     ,   . 
 
Most  of  the  non-linear  mixed-effect  modelling  methods  estimate  the  parameters  using  a  ML 
approach: the data probability is given by a function of the model parameters and parameter 
estimates are chosen to maximize this probability. 
The overall likelihood is the product of all individual likelihoods    and since the likelihood must 
account for the random effects on the individual level, the individual likelihood is expressed as 
the integral over all possible values of   : 
 
    =     
 
    =        | ,  ,   ℎ   |Ω    
 
      [2.1] 
 
where ℎ is a multivariate normal density function with zero mean and covariance matrix  . 
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2.7.   Non-linear  mixed-effect  approach:  NONMEM  as 
software platform 
 
NONMEM version VI (Icon Development Solutions) [42] is a software platform that allows to 
perform population analysis with mixed-effect models and whose name stands for ‘NON linear 
Mixed Effect Modeling’.  
The basic steps for running NONMEM are: 
 
(a)  to organize data input, 
(b) to write the control file, which specifies the mixed-effect model, 
(c)  to run the model and obtain model parameter estimates. 
  
(a) NONMEM needs ‘data input’ files organized into records with some pre-defined items as 
follows. The subject number, called ‘ID’, is the first item in each record. The records appear in 
subject order and, within a subject, they are organized by time if a time series is being analyzed. 
Time specification, called ‘TIME’, is usually the second item in each record. The dependent 
variable, called ‘DV’, is the third one. Additional items can be added if the model requires so, for 
example subject covariates, such as weight, height, gender, etc.  
 
(b) Once data are organized, the model is specified in the ‘control file’, or ‘control stream’, which 
for an estimation problem typically contains the following control elements. 
 
$PROB  States the problem being solved. 
$DATA  Specifies the name of the data file (created at step (a)). 
$INPUT 
List the names of the data records in the input file, in the exact order of data 
file columns. 
$PRED 
Describes ta routine that predicts the observations. It is the main part of the 
control stream in which the mixed effect model is specified. 
$THETA  List the initial estimates of the fixed effects parameters.  
$OMEGA  List the initial estimates of the variance of the inter-individual random effects 
(called ETA’s). Note that if they are all fixed to zero the estimation method . 
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becomes NAD. 
$SIGMA 
List the initial estimates of the variance of the intra-individual random effects 
(called EPS’s). 
$EST 
Provides the parameters that control the estimation process. Typically 
includes: METHOD (indicating which estimation method has to be applied), 
MAX (maximum number of iterations), LIKELIHOOD (indicating whether 
the likelihood is defined by the modeller; this option is necessary in case of 
categorical data modelling). 
$COVARIANCE 
Implies the estimation of the full variance-covariance matrix of the parameter 
estimates. This step is useful to get standard errors of the estimated 
parameters. 
$TABLE  Produces an output table of the results. 
 
 
NONMEM needs specific keywords for each feature of a mixed-effect model, in particular: 
 
(i)  THETA is a fixed effect parameter, i.e. an element of  .; 
(ii)  ETA is an inter-individual random effects, i.e. an element of   ; 
(iii)  EPS is an intra-individual random errors, i.e. an element of   ; 
(iv)  F is the individual model prediction,       ,   ; 
(v)  Y  is  an  observation,      .,  or  the  correspondent  user-defined  likelihood  (if 
LIKELIHOOD is specified in $EST). 
 
NONMEM only deals with normally distributed random variables (ETA’s and EPS’s). However, 
in the $PRED field it is possible to implement three different individual parameter distributions 
(see VAL) and error structures (see Y):  
 
(i)  additive model: 
                 VAL=THETA+ETA 
                 Y=F+EPS 
(ii)  constant coefficient of variation model: 
                VAL=THETA* (1+ETA) 
                 Y=F*(1+EPS) 
(iii)  log-normal model: 
                VAL=THETA*EXP(ETA) 37 
 
                 Y=F*EXP(EPS) 
 
 where VAL stands for the value for the specific individual parameter of interest. 
 
(c) NONMEM estimates model parameters with a ML approach. However, the likelihood of non-
linear mixed-effect models, Equation 2.1, is often difficult to compute in a close form because of 
non-linearity  of  the  random  effects.  To  deal  with  these  problems,  three  methods  have  been 
implemented in NONMEM, all of them based on likelihood approximations: the ‘First Order’, 
the ‘First Order Conditional Estimation’ and the ‘Laplace’ methods. 
 
 
 
2.7.1.  First order 
The First Order (FO) method is the simplest approximation method that can be applied when 
dealing with ML estimation in non-linear mixed-effect modelling. It consists in linearizing the 
mixed-effect model,  
 
   =      ,   ,  ,     +   ,      ~  0,Ω ,       ~  0,     ,   . 
 
(in which the dependency from z has been omitted for simplicity), through a first order Taylor 
expansion around the mean random effects of the population,     = 0: 
 
   =    {   ,  ,   } +    
 
   ≃    {   ,0,   } +
    {   ,0,   }
   
    ,0,   
   
    − 0  +    
 
                                                                                     ,0  
 
   ≃    {   ,0,   } +     ,0    +   . 
 
In this way, the random effects    and the individual errors   , (assumed to be independent) enter 
the  approximation  in  a  linear  way.  Since  they  are  normally  distributed,  also  the  marginal 
distribution of    is normally distributed, with the following first two moments: 
 [  ] =    {   ,0,   }, 
                                   ≃       
   =  [     ,0        ,0     ] +  [    
 ] = . 
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                                          =     ,0  [    
 ]    ,0   +  [    
 ] = 
                                          =     ,0 Ω    ,0   +       ,0,   ,   =     ,0,Ω . 
 
Therefore, for each subject the likelihood is 
 
     ,Ω  =
 
                    
 
 
exp −
 
     −  [  ] 
 
             −  [  ]   = 
          =
 
               , ,    
 / exp −
 
 [   −    {   ,0,   }]     ,0,Ω   [   −    {   ,0,   }]  
 
and the overall likelihood is given by the product of all the individual likelihoods:  
 
   ,Ω  =      ,Ω 
 
   
. 
 
The  population  parameters   =   ,Ω  can  be  estimated  by  maximizing    ,Ω  or,  similarly, 
minimizing the following objective function: 
 
   = −2log    ,Ω  . 
 
For simplifying the notation, let’s call    {   ,0,   } =    . The objective function becomes: 
 
   = −2log   
1
  2    det     ,0,Ω   
 
 
 exp −
1
2
[   −    ]     ,0,Ω   [   −    ] 
 
   
   
 
Individual parameters    are estimated in a second step. In particular, the inter-individual random 
effects are estimated with a ‘Maximum A Posteriori’ (MAP) approach using as prior for the their 
distribution  
  ~  0,Ω   , 
 
where Ω   is the previously estimated population variability. 
In particular, calling      ,   =   ,    estimates are obtained by minimizing: 
 
    =             −          ,  ,     
 
  
      −          ,  ,      +   
 Ω       
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Once the inter-individual random effects are computed, the individual parameters can be obtained 
according to the population model: 
 
     =      ,   ,    
 
This  step  is  called  the  ‘Posthoc  Step’  and  the  estimates  obtained  through  it  are  also  called 
‘Posthoc estimates’ or ‘Empirical Bayes Estimates’ (EBE’s).  
The  First  Order  approximation  method  guarantees  quick  computational  times.  However, 
especially  for  models  that  are  nonlinear  in  the  parameters,  the  approximation  about  the 
expectation of the random effects,     = 0, might be rather poor, resulting in inconsistent estimates 
of the fixed effects: 
 
      →       +      . 
 
2.7.2.  First order conditional estimation 
The ‘First Order Conditional Estimation’ (FOCE) method is a more accurate algorithm. The 
FOCE  algorithm  approximates     by  an  individualized  estimate,   
∗ ,  defined  by  a  second 
optimization problem: 
   ≃    {   ,  
∗,   } +
    {   ,  
∗,   }
   
    ,  
∗,   
   
    −   
∗  +   
∗ 
 
                                                                                     ,  
∗  
 
   ≃    {   ,  
∗,   } +     ,  
∗     −   
∗  +   
∗ 
  
   ≃    {   ,  
∗,   } +     ,  
∗    −     ,  
∗   
∗ +   
∗, 
 
where   
∗~  0,      ,  
∗,   ,   . 
The approximate marginal distribution of    is therefore characterized by the following mean and 
covariance: 
 
 [  ] =    {   ,  
∗,   } −     ,  
∗   
∗ 
                                   ≃     ,  
∗ Ω    ,  
∗   +       ,  
∗,   ,   =     ,  
∗,Ω  
 . 
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The overall likelihood, obtained as in the FO approximation method, can be used for estimating 
  ,Ω . These population estimates can be subsequently used to update the estimates for   . 
 
2.7.3.  Laplace approximation 
Laplace  method  is  based  on  the  Laplacian  approximation  of  the  exact  marginal  likelihood 
specified by the hierarchical nonlinear model: 
 
  =    
 
   
=       | ,  ,   ℎ   |Ω    
 
   
. 
 
Given a complex integral,        ,      can be re-expressed as          =       and      can 
be approximated by a second-order Taylor expansion around a point    as: 
 
     ≃       +    −           +
   −     
2!
       . 
 
The approximated integration is the first order Laplacian approximation to the true integration: 
 
          =          =   
                   
       
 !          .  [2.2] 
 
The  Laplacian  approximation  given  by  Equation  2.2,  considering      as     and  therefore 
    | ,  ,   ℎ   |Ω  as     , allows to compute the approximated likelihood in close form. The 
approximation implemented in NONMEM is around the conditional estimates of     for the non-
linear model. The conditional estimates or the empirical Bayes estimates (EBE) of    are the best 
predictors of the random effects   . 
  
 
2.8. Categorical data likelihood 
 
Data can be considered as continuous or categorical. Continuous data consist of variables with an 
infinite number of values, while categorical data consist of variables taking values in a finite set 
and can therefore be placed into mutually exclusive categories.  
Categorical data can be further divided into nominal or ordinal. The nominal ones are unordered 
and can be classified by ‘names’, while the ordinal ones have a natural order and can be organized 
into ‘levels’, even if the exact distance between the levels is generally unknown. Examples of 41 
 
nominal categorical variables are race or sex, while examples of ordinal categorical variables are 
age or pain intensity (e.g., absent, mild, moderate, severe). 
Sleep data can be considered as categorical data: sleep data derived from PSG recordings can be 
‘categorized’ into 6 mutually exclusive categories (AW, ST1, ST2, ST3, ST4, REM), according to 
the  criteria  illustrated  in  Chapter  1.  Such  categories  do  not  have  a  recognized  natural  order, 
therefore sleep data can be considered as nominal categorical data.  
Modeling categorical data is slightly more complex than modeling continuous ones. There are two 
major differences between models for continuous and categorical data analysis: 
(a)  the  probability  of  a  certain  outcome,  rather  than  the  values  of  the  outcome  itself,  is 
modeled; 
(b) consequently, no residual error is defined in the model. 
 
The model for categorical data becomes: 
 
    =       ,   ,  ,    ,         ~  0,Ω , 
 
where     is the probability of a certain outcome for the i-th subject at time   .  
Consequently, each observation’s likelihood is the probability of the observation itself as it is 
modeled, and the likelihood of Equation 2.1,     | ,   , can be expressed by the product of the 
probabilities  of  the  outcomes.  Such  likelihood  is  said  ‘user-defined’,  because  it  is  explicitly 
defined  in  the  model.  In  this  case  the  only  estimation  method  which  can  be  adopted  with 
NONMEM VI is the Laplace one. A more detailed explanation on likelihood expression in case of 
categorical data and in the specific Markov-chain model context is provided in Chapter 3.2.8.  
 
 
2.9.  Conclusion 
 
In this chapter we have provided an overview of different estimation methods with a primary 
focus on the mixed-effect approach in a context of categorical data. In the next chapter a full 
description  of  the  key  features  of  the  Multinomial  Markov-Chain  model  for  the  analysis  of 
polisomography data will be presented together with relevant information about data collected in 
a recent clinical study in primary insomnia.  
 . 
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Chapter 3 
A Markov-chain model
polysomnographic signals
 
 
 
3.1.  Transitions between sleep stages and Markov chains: 
state of art 
 
As mentioned in the first chapter, polysomnography 
parameters (LPS, WASO, etc) characterizing patients’ sleep quality. The clinical efficacy of an 
hypnotic compound is usually evaluated on the basis of its effects on these aggregated parameters. 
However, this kind of approach 
under examination and provide
Besides  supplying  values  for  the  aggregated  parameters,  polysomnography 
assessment of the sleep stages occurring during the 8
is determined on a 30-second temporal grid and is therefore made of 960 ‘samples’, one for each 
‘epoch’ (30 second interval). Each sequence can be considered as
stochastic  process  assuming  values  in  a  finite  discrete  set,  i.e.  the  sleep  stages.
appropriate mathematical model
stages time-courses over the night.
Figure 3.1. A realization of sleep stochastic process.
chain model for the study of 
polysomnographic signals 
Transitions between sleep stages and Markov chains: 
As mentioned in the first chapter, polysomnography allows to evaluate some relevant clinical 
parameters (LPS, WASO, etc) characterizing patients’ sleep quality. The clinical efficacy of an 
hypnotic compound is usually evaluated on the basis of its effects on these aggregated parameters. 
roach brings mainly to the evaluation of the overall effect of the drug 
under examination and provides only few insights on the internal structure of sleep. 
esides  supplying  values  for  the  aggregated  parameters,  polysomnography 
the sleep stages occurring during the 8-hour night time (Figure 3.1)
second temporal grid and is therefore made of 960 ‘samples’, one for each 
econd interval). Each sequence can be considered as a realization of a finite discrete 
stochastic  process  assuming  values  in  a  finite  discrete  set,  i.e.  the  sleep  stages.
mathematical models can describe sleep structure allowing to predict feasible sleep 
courses over the night. 
Figure 3.1. A realization of sleep stochastic process. 
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to evaluate some relevant clinical 
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Since, as illustrated in paragraph 1.1.4, there are specific sleep patterns with some preferential 
transitions,  sleep  stages  can  be  considered  as  a  sequence  of  stochastic  variables  with  some 
dependency among each other. 
A mathematical model able to describe this feature is the ‘Markov chain model’, whose basic 
concepts  are  those  of  state  and  state  transition.  The  ‘Markov-chain  model’  determines  the 
probabilities of transitioning between different states based on the recent and the present states or, 
in the less general case, on the present state only. Such model is adaptable to a large variety of 
situations: for example, it can be applied to the classic stochastic problem of the Drunkard’s 
Walk, in which the position reached in the next step only depends on the present position and not 
on the way this present position was reached. It can be also used to predict weather conditions 
given the weather on the previous days or to describe all the board games played with dice 
(Monopoly for example), in which the future position on the board depends only on the current 
state and the next roll of the dice. 
Some  attempts  to  apply  a  Markov-chain  model  for  describing  sleep  data  are  reported  in  the 
literature:  in  2002  Gregory  and  Cabeza  [43]  used  this  approach  for  describing  the  internal 
architecture of sleep in rats. However, they modeled sleep as a two-state process, considering only 
REM and non-REM sleep. Kemp et al. [44] modeled rates of transition among the various sleep 
stages, but either assumed constant rates throughout the night or estimated their dynamics by 
smoothing  observed  transition  frequencies  by  hand.  More  recently,  Karlsson  et  al.  [1]  and 
Kjellsson et al. [3] proposed a Markov-chain model using a mixed-effect approach and modeling 
the transition probabilities among different stages as binary logistic functions. Finally, the model I 
validate here [2] is a refinement of the latter model, which considers the transition probabilities as 
multinomial logistic functions. 
This chapter provides some mathematical background on Markov-chain models, the description 
of the sleep data used for its implementation and the presentation of specific features adopted in 
order to maximize the data likelihood. 
 
 
3.2.  Markov-chains: mathematical definitions 
Let a random process be a finite sequence   = {  }    = {  ,  ,…} of random variables taking 
values in a discrete set  . The elements of   are called ‘states’ of the system and thus   the ‘state 
space’. 
The index t of    is usually thought as a ‘time index’, even though it is not necessarily related to 
the concept of time, but rather expressing the ordered evolution of the process. Consequently,    
represents the state of the process at ‘time’ zt, where z is the ‘time’ vector. 45 
 
The process   = {  ,  ,…} is called ‘Markov chain’ if it the conditional probability between the 
outcomes at different times satisfies the ‘Markov property’. 
 
Definition 3.1. The sequence {  ,  ,…} of random variables taking values in   is said to have 
the Markov property if 
 
       =       |    =   ,      =      ,…,    =     =        =      |    =     
 
for every sequence   ,… ,   ,       of elements of   and for every   ≥ 1. 
 
This property states that the probability of an event one step into the future conditioned on the 
entire past up to the present time t is equal to the conditional probability of the future event given 
just the present one. In particular, a sequence of such random variables is said to be a ‘First-order 
Markov chain process’ because each outcome depends exclusively on the previous state.  
Definition 3.2. The process   is an ‘Nth-order Markov chain process’ if the dependency between 
the random variables constituting the process involves N successive steps in the sequence, that is 
if the probability of the future outcome is conditioned on the N previous states: 
 
       =       |    =   ,…,    =     =        =      |    =   ,…,      =      . 
 
Definition 3.3. Given a First-order Markov chain process   = {  ,  ,…}  with k and m in its 
state space  , the conditional probability 
 
       =        =   |    =    ≥ 0 
 
is called the ‘transition probability’ from k to m at time zt. If the transition probabilities do not 
depend on time, i.e.        =       + ℎ  =    , ∀  ∊ ℕ ,∀ℎ ∊ ℕ  , the Markov chain is said 
to be ‘time-homogeneous’.  
 
Assuming  a  finite  state space  , that  is   = {0,1,…, };,  it is useful to  collect the transition 
probabilities from/to the states of   in a matrix: 
 
     =  
             
             
⋯       
⋯       
⋮ ⋮
             
⋮ ⋮
⋯       
 ,, 
 . 
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which  is  called ‘transition  probability  matrix’.  Each  row  of      represents  all  the  transition 
probabilities from a single state of  : therefore, the probabilities in each row must sum up to 1:  
 
         = 1
 
   
, ∀   ∈  .   
 
Assuming to observe M independent realizations of the process of the same length N: 
 
     = {   ,   ,   ,…,   } 
     = {   ,   ,   ,…,   } 
…… 
     = {   ,   ,   ,…,   }, 
 
it is possible to define some statistics depending on the data: 
•      ≜ number of transitions from state k to state m in all the realizations, 
•     ≜ number of transition starting from state k, 
•     ≜ total number of transitions in the data, 
•      ≜ number of occurrences of state k in the data. 
 
Once these statistics are available, the frequency of occurrence of each stage is computed as: 
 
       =
   
     
 
   
, ∀    ∊  ,  [3.1] 
, 
and the 'transition frequencies' between stages are calculated as: 
 
         =
   
  
, ∀  ,  ∊    [3.2] 
 
Every single realization of the process can be considered as a path in time through the state space, 
and its probability 
 
     ,…,    =    ,…,     
 
is just the joint probability of    ,…,   . It is possible to demonstrate that, according to the 
Markov property characterizing the process, such joint probability can be expressed in terms of 
the transition probabilities and the probability mass function of   : 47 
 
 
Theorem  3.1.  For  a  Markov  chain    and  for  any  path {  ,  ,  ,…,  },  the  conditional 
probability of the path conditioned on the first value is the product of the transition probabilities 
between successive states of the path: 
 
       ,…,    =    ,…,       =     =            ⋯         [3.3] 
 
and consequently the probability (not-conditioned) of the path is: 
 
       ,…,    =    ,…,     =      =                ⋯         [3.4] 
           
 
3.3.  Implementation  of  Markov-chains  is  sleep  data 
modeling 
 
As already mentioned, sleep data can be considered as realizations of a Markov-chain process 
with S = (AW, ST1, ST2, ST3, ST4, REM). 
The  model  developed  in  [2]  is  a  time-non-homogeneous  Markov-chain  model  which  uses 
multinomial logistic functions for describing transition probabilities between states and uses a 
mixed-effect approach for describing their parameters. 
The following paragraphs present the clinical data obtained from PSG together with the specific 
model features applied to the Markov-chain model as proposed by Bizzotto et al. [2]. 
 
3.3.1.  Clinical study 
Data were obtained from a polysomnograghic multi-centre, randomized, double-blind, placebo-
controlled, parallel three-arm study designed to investigate a new candidate drug [Fig 3.2]. Male 
and  female  subjects  (18-64  years  of  age)  diagnosed  with  primary  insomnia  were  chosen  as 
feasible candidates for the study. The eligibility of the subjects was determined on the basis of 
specific PSG variables (e.g., LPS, WASO) obtained after a screening period consisting of a first 
clinical screening visit followed by a 2-night PSG recording in a sleep laboratory. After a week of 
daily placebo administration, subjects were randomized in the study, each arm assuming placebo 
or  two  different  doses  of  the  drug  for  28  days  before  bedtime.  PSG  was  recorded  in  three 
occasions in two consecutive days (1-2, 13-14 and 27-28) for each arm of the study. 
Subjects  taking  part in the  selection  for this  study  had  a  diagnosis  of  primary  insomnia  and 
insomnia symptoms for at least three months, according to the 'Diagnostic and Statistical Manual . 
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of Mental Disorders - Fourth Edition - Text Revision (DSM - IV - TR)', [33] criteria 307.42. For 
being included in the study, the mean of PSG variables obtained after the two screening nights 
had to fall within the following ranges: 
 
•  mean TST: between 240 and 390 minutes, 
•  mean LPS: more than 30 minutes and not less than 20 minutes on either night, 
•  mean WASO: more than 60 minutes and neither night less than 45 minutes. 
 
 
 
Figure 3.2: Clinical study protocol. 
 
The model was developed based only on the first night of the double-blind treatment nights, from 
M=116 patients treated with placebo. Since few epochs of stages 3 and 4 were reported, they were 
merged in a single stage called ‘slow wave sleep’ stage. 
Therefore the stages considered are the awake stage (AW), stage 1 sleep (ST1), stage 2 sleep 
(ST2), slow wave sleep (SWS) and REM sleep (REM) and the state space is    = {AW, ST1, ST2, 
SWS, REM}. 
The sequence of sleep stages can be thought as: 
 
     = {   ,   ,   ,…,   } 
     = {   ,   ,   ,…,   } 
…… 
     = {   ,   ,   ,…,   }, 
 
where N = 960 is the number of samples for each subject and M = 116 is the number of subjects. 
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3.3.2.  Multinomial logistic function 
Let     represent the state (i.e. the sleep stage) of the i-th patient at epoch t and let each single 
realization  of  the  process  (i.e.  each  patient’s  sequence)  obey  to  a  first-order  Markov-chain, 
according to Definition 3.1. 
Let then the binary variable       represent the transition of the i-th individual from state k at 
epoch (t-1) to state m at epoch t, that is: 
 
                                                        1   if          =   and     =  , with  ,  ∊   
                                       = 
                                                        0   otherwise 
 
Then, for given values of k ∊   (i.e. the starting state of a transition) and for a given time t ∊ {1, 2, 
… , N} the vector 
 
       = [      ,       ,…,       ] 
 
is a multinomial random variable representing all the possible transitions from state k at time t. 
This multinomial random variable is characterized by its probability vector: 
 
          = [        ,         ,…,         ]  [3.5] 
 
where          =       =  |        =    ≥ 0 is the probability of moving from k to m at time t.  
Since         is the k-th row of the transition probability matrix characterizing the process at time 
t, 
         
 ∈ 
= 1. 
 
The model for the transition from the state k of the chain is therefore 
 
         |         ∼                     .  [3.6] 
 
In  our  context,  the  transition  probabilities  represent  the  model  parameters  to  be  estimated 
according to the sleep data. To avoid estimates constrained between 0 and 1, it is often useful to 
describe such parameters as logistic functions [3]. . 
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The logit of a probability p describing a random variable is defined as the logarithm of its odds, 
that  is  the  logarithm  of  the  probability  of  achieving  a  favorable  outcome  divided  by  the 
probability of failing: 
 
  =    
 
 1 −   
 
 
The logit function allows therefore to transform a probability into a not constrained variable, as 
shown in figure 3.3. 
 
 
Figure 3.3: The binary logit function. 
 
Since the transitions from a single state of   come from a multinomial distribution (Equation 3.6), 
they are transformed into multinomial logit functions. For each subject i, each starting state k and 
each epoch t the logits for the model are defined as: 
 
        =    
       
       , 
 
where m takes all the values in  . 
In such a way, it is possible to define for each triple (i, k, t) 5 different logit functions, one of 
which is equal to zero. Taking, for example, the transitions from the AW state at time t, it is 
possible to define the following logits: 
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                                                                        =    
         
           
                                                                         =    
          
          
                                                                         =    
          
          
                                                                        =    
          
          
                                                                        =    
          
          
 
The  corresponding  transition  probabilities  can  be  therefore  obtained  as  multinomial  logistic 
functions: 
 
                                                                 =
         
          
                                                                   =
          
                                        
                                                                      … 
 
                                                                 =
          
         
 
 
 
                                                            =           
                                                             =                  ·           
                                                                         …  [3.7] 
 
                                                             =                 ·           
 
Recalling then that their sum must be equal to 1: 
 
          +            +            +            +            = 1 
          +                 ·           + ⋯+                 ·           = 1 
 
          = 1/ 1 +                 +                 +                
+                  
 
it  is  possible  to  compute  all  the  transition  probabilities  from  AW  substituting           in 
Equations 3.7. 
Therefore the probability of the transition from k to m at time t is given by: . 
 
52             
 
 
          =
             
                ∊   
  [3.8] 
 
Hence, instead of the probability vectors         defined in equation 3.5 the parameters of the 
model are the corresponding logit vectors: 
 
          = [        ,         ,…,         ],   ∊  ,i ∊ {1,…, },  ∊ {1,…, }  [3.9] 
 
which fully characterize the model. Note that if no correlation is assumed between logits with 
different values for k, i.e. for different stages of departure, the model can be divided into five 
different smaller models. Each sub-model, referred to as ’sub-model k’, describes the transitions 
from a specific sleep stage and its parameters can be identified separately from the others. 
Each sub-model is estimated using a non-linear mixed-effect approach for taking the variability of 
the population into consideration. That is, each individual logit          is thought to be normally 
distributed around its typical value: 
 
       ~        ,  
      , 
 
where        is the typical value for the logit and   
      is the variance of the inter-individual 
distribution. Considering the vector-matrix notation 
 
         ~        ,Ω       [3.10] 
 
where         is the vector of Equation 3.9 and is assumed normally distributed around the vector 
of population values for the logit functions        with covariance matrix Ω    . 
 
 
3.3.3.  Time dependence of model parameters 
As introduced in the first chapter, sleep physiology varies over night time. Consequently, it is 
logical to assume that the transition probabilities of our model depend on time, this means that the 
Markov-chain model is non-homogeneous. The temporal dependence of logit functions         
with respect to night time is modeled as a piecewise linear function with three break-points BP = 
(BPA, BPB, BPC).  BPA and BPC are selected at the beginning and at the end of the night 
window, while BPB is estimated according to the maximum likelihood principle and is assumed 
to be common to the whole population (no inter-individual variability on it). 53 
 
The parameters of the model defined so far are the logit population values at the 3 break-points, 
the associated inter-individual variability and BPB. The population logits are expressed by the 
following vectors: 
 
     = [     ,      ,…,       ] 
     = [     ,      ,…,       ] 
     = [     ,      ,…,       ], 
 
in which the letters A, B, C refer to the night time break-points BPA, BPB, BPC.  The individual 
deviation of a specific logit function from its typical value is constrained to be constant at the 
different break-points, meaning that the individual logits in BP can be expressed by: 
 
                                                 = [     ,     ,      ]  [3.11] 
                                                    = [      +        ,      +        ,       +        ] 
 
where      ,    ,      are  the  typical  population  values  of  the  logit  characterizing  the 
transition from k to m at times BP = [BPA, BPB, BPC] and        is the individual deviation from 
this logit. 
The individual deviation        is assumed to be drawn from a normal distribution having zero 
mean and variance   
  , that is:       ~  0,  
   . 
Once       are known, ∀i ∊{1, ..., M}, k ∊   and m ∊  -{k}, each logit time-course over the night, 
       , is given by linear interpolation of the logit values at two adjacent break-points.  
Going back to the vector-matrix notation, Equation 3.10 becomes 
 
         ~        ,Ω    [3.12] 
 
where the covariance matrix  Ω  is supposed to be not time-depending. 
Finally, the transition probabilities profiles are calculated as anti-logit, as described in Equation 
3.8. The typical probability profiles estimated from the available dataset for the transitions from 
ST1 are shown in Figure 3.4. This plot highlights the property of the Markov-chain model built on 
multinomial logistic functions: by construction, probabilities sum up to one for each time of the 
night. Figure 3.5 shows the probability profile for the specific transition from ST1 to ST2 with the 
corresponding 90% prediction interval for the population distribution. . 
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Figure 3.4: All the typical transition probabilities from ST1 estimated from the available dataset 
 
 
 
 
Figure 3.5: Typical transition probability from ST1 to ST2 with the corresponding 90% prediction interval on the 
between subject variability. 
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3.3.4.  Stage time effect 
According to the sleep physiology, as presented in Chapter 1, the probability of moving from or 
staying in a specific stage k is influenced by the duration of contiguous time spent in stage k. This 
duration, also defined as the time elapsed since the last change in sleep stage, is called ‘stage 
time’,  (   or  STT).  The  stage  time  has  been  introduced  in  the  model  as  a  predictor  for  the 
parameter values and is supposed to modify the logits at the night-time break-points according to 
an additive law. A temporal grid is defined on the stage time and three break-points, BPs = [BPsa, 
BPsb, BPsc] are defined on it:  
•  BPsa, the first break-point, at t = 1 epoch, that is the minimum stage time that can be 
observed  
•  BPsc, the last break-point, at the maximum stage time observed in the data with respect to 
the particular stage of departure 
•  BPsb, the central one, to be estimated as a parameter of the model.  
The temporal grid is therefore divided into two segments on which the ‘stage time effect’ (STE) is 
modeled  as  a  piecewise  linear  function  of  stage  time.  Considering  a  generic  stage   ∊   of 
departure new vectors are introduced ∀m ∊  -{k} : 
 
       = [    ,    ,    ]  [3.13] 
 
where     ,     ,      are the additive effects that stage time has on the logit defined on the 
transition from k to m for    = BPsa,    = BPsb and    = BPsc, respectively. Obviously, no effect 
is assumed  for    =  BPsa, (     = 0,   ∀ ,  ∊  ).  In  each  segment  of  the  temporal  grid  the 
deviation from the logit predicted by the model is therefore calculated by linear interpolation as: 
 
       if       ≤    ≤      
                          =      ·       −    /      −       +      ·     −      /      −       
                                  =      ·     −      /      −       
      endif 
 
       if       <    ≤      
                          =      ·       −    /      −       +      ·     −      /      −       
      endif 
 
being          the stage time effect for stage time equal to   . 
No inter-individual variability is assumed, so that the stage time influences the whole population 
in the same manner. Moreover, each stage time effect         is supposed to equally modify the . 
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corresponding logit values       at the three night time break-points BP = [BPA, BPB, BPC]. 
New vectors including the stage time effect are therefore defined in place of those of Equation 
3.1: 
 
          = [         ,         ,          ]  [3.14]                                  
                = [      +        +         ,      +        +         ,       +        +         ] 
 
Once           are known, ∀i ∊{1, ..., M}, k ∊   and m ∊  -{k}, each logit time-course over the 
night (      ,   , function of    and  ) is given by linear interpolation of the logit values at two 
adjacent break-points. 
Figure 3.6 exemplifies how the stage time effect (red line) modifies an individual logit (blue line). 
 
 
Figure 3.6: An illustrative example on how the individual deviation from the typical behavior and the stage time effect 
(STE) can affect a logit profile over the night time. 
 
The  stage  time  effects  estimated  on  the  available  data  over  the  stage  time  are  shown  as 
exponential terms in Figure 3.7. The choice to report an exponential value is related to the logit 
transformation properties. In this way the additive effect of the STE on the logits is equivalent to a 
multiplicative  effect  on  probabilities  ratios.  For  example,  ‘AW  /  REM’  in  the  ‘REM’  plot 
indicates the multiplicative STE on 
          
            obtained as the exponential for the additive STE 
on            =    
          
           . 
 The  night  time  profiles  of  the transition  probabilities  are  again  calculated  as  anti-logit  from 
      ,   , as in Equation 3.8. 57 
 
 
Figure 3.7: Exponential of the stage time effects estimated on the available dataset for all the logits. 
 
Figure 3.8 presents the estimated probability profiles for the transitions from ST1, ST2, SWS and 
REM  at  different  stage  times.  In  particular,  the  left  column  shows  the  probability  profiles 
estimated for    eqaul to 0.5 minutes (i.e. 1 epoch, when no stage time effect is considered), while 
the right one shows those obtained for    equal to the median stage time over the whole night 
time. The left and right plots for transitions from ST1 are equal, since the median stage time in 
this case is 1 epoch only (reflecting the fact that stage 1 sleep is a rapid transitional state in sleep). 
Differently from the plots that illustrates the transition probabilities along the night time, the stage 
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time appears to be an informative predictor as shown by the dynamic relation between it and the 
STE  (Figure  3.7).  Plots  for  transitions  from  awake  are  shown  in  Paragraph  3.2.7,  after  the 
inclusion of an additional model feature.  
 
Figure 3.8: Typical transition probabilities for the stage1, stage2, sws and rem sub-models. In the left column the 
profiles are computed for stage time = 0.5 minutes, while in the right one they are computed for the median stage time 
observed in the data. 
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3.3.5.  Transition probabilities fixed to zero 
It is known that some of the 25 hypothetically possible transitions between sleep stages occur 
very  hardly.  The  available  dataset  confirms  this  statement,  as  shown  by  the  'transition 
frequencies', computed as in Equation 3.1, and here reported: 
 
FROM\TO  AW  ST1  ST2  SWS  REM 
AW  0.8303  0.1246  0.0321  0.0006  0.0125 
ST1  0.1350  0.4183  0.3471  0.0006  0.0990 
ST2  0.0399  0.0381  0.8737  0.0362  0.0121 
SWS  0.0207  0.0046  0.1418  0.8324  0.0005 
REM  0.0522  0.0540  0.0132  0  0.8806 
 
Table 3.1: Transition frequencies computed from data. 
 
Some transition frequencies are very low and are therefore fixed to zero in order to simplify 
model identification. The chosen frequency threshold is 0.1% so that the transition frequencies 
highlighted in red are assumed equal to zero. 
This  implies  that  the  sub-models  awake,  stage1,  sws  and  rem  need  one  less  logit  each. 
Summarizing, the logits considered for each sub-model are shown in table 3.2. 
 
logit\sub-model  awake  stage1  stage2  sws  rem 
1           ,              ,              ,              ,              ,    
2           ,               ,               ,               ,               ,    
3           ,               ,               ,               ,               ,    
4                ,        
 
Table 3.2: Logits for the different sub-models. 
 
 
3.3.6.  Inter-individual variability 
The assumption explained in the previous paragraph implies that the covariance matrices Ω  of 
awake, stage1, sws and rem sub-models have dimension 3x3, while the covariance matrix for 
stage2 sub-model has dimension 4x4. Full covariance matrices were initially assumed. 
The  statistical  significance  of  each  element  of  these  matrices  was  assessed  according  to  'log 
likelihood ratio test'. Only correlations that achieved statistical significance were included in the 
final model and are here reported: 
 . 
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•  awake, using an inter-individual covariance between: 
(i)          ,     and          ,     when    = 0, 
 
•  stage1, using an inter-individual covariance between: 
(i)          ,     and           ,   , (   = 0), 
(ii)           ,    and           ,   , (   = 0), 
(iii)          ,    and           ,    , (   = 0). 
 
Using the following notation for expressing the covariance elements of Ω : 
 
  
    =           ,   ,      ,            = 0 , 
 
the corresponding covariance matrices are: 
 
Ω   =  
  
     
  
        
0
  
  
        
  
     
0
  
0
0
  
     
 , 
 
Ω    =  
  
     
  
        
  
        
  
  
        
  
      
  
         
  
  
        
  
        
  
      
 . 
 
Furthermore, it was found that also the between subject variability on the logit            of the 
rem sub-model can be fixed to zero, resulting in the following covariance matrix: 
 
Ω    =     
0
0
0
    
0
  
      
0
  
0
0
  
      
 . 
 
 
3.3.7.  Initial sleeplessness 
One additional feature has been introduced in the model to differentiate the sleep physiology 
time-course between initial sleeplessness and rest of the night. Consequently, the 8-hour night 
time is divided into 2 parts: the first ranging from t = 2 epochs to t = IS, where IS ('Initial 
Sleeplessness') is the first epoch in which a non-awake state is observed in a specific subject, and 
the second one filling the remaining part of the night. In the second time interval the logits are 61 
 
modeled as previously described changing only the position of the first break point of the night 
time: BPA=IS. 
The logits in the first part of the night are modeled again as piecewise linear functions, but no 
inter-individual variability or stage-time effects are considered. Therefore, the logits in this time 
interval are simply estimated as population parameters. In particular, three additional break-points 
are defined, Bpi = [BP1, BP2, BP3], where: 
•  BP1 is the first one at t = 2 epochs  
•  BP3 is the last one at the maximum IS observed in the data 
•  BP2 is the central one and it is considered as an additional parameter to be estimated. 
Figure 3.9 shows the estimated typical transition probabilities for the awake sub-model: in the left 
plot no stage time effect is considered, while in the right one stage time effect is considered and 
fixed to the value estimated for the median awake time observed in the data. The discontinuity in 
the profiles for t = BPA is due to the introduction of the Initial Sleeplessness feature. 
 
 
Figure 3.9: Typical transition probabilities for the awake sub-model. In the left column the profiles are computed for 
stage time = 0.5 minutes, while in the right one for the median stage time. 
 
In conclusion, Figure 3.10 shows all the typical transition probabilities with their 90% prediction 
interval on the between subject variability according to the final model. Note that the profiles for 
the transitions from AW show inter-individual variability in the second part of the night only, 
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Figure 3.10: All the typical transition probabilities with the corresponding 90% prediction interval on the between 
subject variability. 
 
 
3.3.8.  Likelihood  
Each sub-model was identified using a maximum likelihood approach. As introduced in Chapter 
2.5, the individual likelihood is expressed as the integral over all possible values of   : 
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where    = data from individual i,   = population parameters,    = random effects on i and ℎ is a 
multivariate normal density function with zero mean and covariance matrix  (covariates are not 
considered in this model). In our case, i.e. categorical data, the Markov-chain model describes 
transition  probabilities  between  observations,  instead  of  actual  observation  values  as  with 
continuous data. The probability of a whole realization for the individual i is therefore given by 
the product of the probabilities of the transitions occurred along the night, as stated in Theorem 
3.1, considering as first state of the chain the AW state (     =     = 1). Therefore,     | ,    
can be expressed as a product of transition probabilities, the ones which actually occurred, so that 
maximizing the likelihood is equivalent to maximizing the probability of the actually occurred 
path. Each transition probability is defined in the model as function of various logits, that is 
 
        =               ,    ,         ∀ triple (i, k, t). 
 
Here, m(t) indicates that m depends on t and is equal to    , and  
 
      ,    = [       ,   ,        ,   ,        ,   ,        ,   ,        ,   ], 
 
with ts equal to the stage time observed at night time t for the subject i (      ,    depends on   
and    according to the model structure). 
Considering sub-model k, the likelihood contribution from individual i is, therefore, defined by 
 
    =                    ,    
 :         
 ℎ   |     . 
 
The overall likelihood function Lk for sub-model k is then the product of the contributions from all 
the individuals. Each likelihood Lk is maximized using the Laplace method in NONMEM version 
VI (ICON Development Solutions.) [42].  
 
 
3.4.  Conclusions 
 
The Multinomial Mixed-Effect Markov-chain model presented in detail in this Chapter has been 
developed [2] with the precise intent of providing a useful tool for analyzing sleep data in their 
dynamic  behaviour  along  the  night.  This  model  therefore  can  be  extensively  applied  in  the 
analysis  of  clinical  studies  that  investigate  the  efficacy  of  sleep  promoting  drugs.  A  proper . 
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evaluation  of  model  performances  is  therefore  of  particular  importance.  Different  diagnostic 
methods to evaluate model adequacy are discussed in Chapter 4 with particular emphasis on those 
based on stochastic simulation. 
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Chapter 4 
Assessment of the model against data 
     
 
 
4.1.  Introduction to diagnostic methods 
 
Mixed-effect models are increasingly used in the pharmaceutical field to analyze and interpret 
clinical data in a context of population framework and to perform clinical trial simulations. The 
latter, when properly performed, constitute a valid alternative to extensive studies, since they 
allow the evaluation of the individual responses to a specific treatment, and consequently the drug 
efficacy and safety in the whole population.  
The  Markov-model  built  for  describing  sleep  architecture  and  characterized  in  the  previous 
chapter has been mainly developed with the intent of providing a useful tool for clinical trial 
simulations. The aim of this thesis is therefore to investigate its performance, evaluating model 
robustness and potential model misspecifications. In practice, we are interest to understand if the 
proposed model adequately interprets the underlying process, providing precise predictions for the 
parameters of interest and avoiding biased estimates.  
Statistical theory indicates several diagnostic methods to check model adequacy, most of them 
involving graphics. In 2007, Karlsson and Savic [4] published a detailed overview of the different 
model diagnostics to be used in the context of mixed-effect modeling, highlighting for each of 
them pros and cons. The authors divided such methods into five categories: 
 
(a)  typical individual prediction-based methods, 
(b) individual parameter estimates-based methods, 
(c)  residual-based diagnostics, 
(d) numerical diagnostics, 
(e)  simulation-based diagnostics. 
 
The  (a)  and  (b)  methods  are  essentially  based  on  graphics:  their  aim  is  to  visually  evaluate 
whether there is agreement between the dependent variable (DV), i.e. the observations we want to 
describe, and population or individual model predictions, respectively. The first method can be 
misleading  when  applied  to  non-linear  mixed-effect  models  and  often  indicates  misspecified . 
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models even when they are adequate. The second one suffers from the opposite drawback: in case 
of sparse information in the individual data, it becomes difficult to recognize misspecified models 
since excellent predictions are usually produced (‘perfect fit’ phenomenon). The residual based 
diagnostics (c), consisting in checking population or individual residual, are strictly connected to 
the latter methods and substantially have the same flaws.  
However, these methods (a, b and c), often referred to as 'goodness of fit inspection methods’, are 
very  easily  implementable  but  not  applicable  in  the  categorical  data  context,  in  which  only 
probability of observations is estimated and, consequently, residuals are not considered. For this 
reason, they are not used in this thesis.    
Several types of numerical diagnostics (d) can be implemented for checking models adequacy in 
case  of  categorical  data.  These  methods  are  essential  importance  for  model  comparison 
(Loglikelihood ratio test), for the evaluation of model robustness (bootstrap) and for the detection 
of possible overfit (standard errors for the parameters). Most of them were used during model 
building procedure, but are not part of this thesis. 
Finally, the simulation based methods (e) are considered the most interesting diagnostics in the 
current use: when dealing with categorical data. In fact, these methods appear very attractive 
because they preserve the same pros of the classical 'goodness of fit inspection methods’ without 
being affected by their cons. Such diagnostics consist in comparing a desired statistic derived 
from raw data with a reference distribution obtained trough stochastic simulation.  
A stochastic simulation is a methodology which aims to re-produce a desired set of data from one 
model  through  random  sampling  from  probability  distributions  defined  by  the  model.  When 
repeated  many  times,  this  procedure  becomes  a  useful  tool  to  show  potential  model 
misspecifications. In fact, when the model is adequate the simulations should mimic real data 
behavior.  
In this Chapter such methods together with their application to the final model are discussed in 
details. However, it is important to highlight that their application, in addition to that of numerical 
diagnostics, played an essential role also during the whole model building process, allowing to 
achieve significant model improvements. 
In particular, our aim in applying stochastic simulation-based methods to the final model is not 
only to check its capabilities in predicting the aggregated parameters (WASO, LPS, etc.) used in 
the clinical practice for quantifying the severity of sleep disorders, but mainly to evaluate its 
predictability  of  sleep  physiological  pattern  whose maintenance  has  been  demonstrated  to  be 
relevant.  The  two  inspections  were  performed  through  the  implementation  of  ’Posterior 
Predictive Check’ (PPC) on the aggregated parameters and ’Visual Predictive Check‘ (VPC) on 
specific statistics derived from data, as the transition frequencies and the stage frequencies.  
However, bias and imprecision in the desired predictions may depend not only on possible model 
misspecifications but also on non robust estimation methods. In the case of the Markov chain 67 
 
model, which is complex, highly non-linear and dealing with categorical data, this issue could 
become very relevant. 
For this reason, a recent approach [6,7] for checking both model adequacy and estimation method 
performance is implemented in this thesis: the ‘Stochastic Simulations followed by Estimation’ 
(SSE) based diagnostics. SSE is a two-stage method which consists in the following steps:  
1.  to simulate a data set from a model with the parameter values estimated  
from the observed data, 
                               2.    to re-estimate the same model on the simulated data, 
                               3.    to repeat steps 1 and 2 many times. 
 
In addition to the evaluation of model robustness and misspecifications, simulation followed by 
re-estimation has been proposed for the assessment of the performance of the estimation method. 
This is particular critical in our specific case where the estimation method (ML approach) is based 
on the likelihood as defined by the user and its approximation according to the Laplacian method, 
as implemented in NONMEM VI. These complexities related to the estimation method should be 
clearly  considered  in  the  validation  procedure.  SSE  is  used  here  for  the  visual  comparison 
between the transition probabilities estimated from raw data and the confidence intervals on the 
correspondent  transition  probabilities  estimated  during  SSE  procedure.  At  the  best  of  my 
knowledge, this kind of visual comparison was never implemented before. We propose to call it 
‘Visual Estimation Check’ (VEC), that reflects the similarity with ‘VPC’ relative to the evaluation 
of the ‘estimation’ procedure.  
 
 
4.2. Simulation-based diagnostics: theory 
 
The theory of Bayesian inference is now recalled in order to give an adequate theoretical basis to 
the  simulation-based  validation  methods  implemented  here.  In  general,  statistical  inference 
consists  in  making  conclusions  from  numerical  data  about  quantities  that  are  not  directly 
observable or quantities potentially observable but not yet observed. In the Bayesian framework, 
the  model  for  describing  such  quantities  is  a  'full  probability  model'  which  combines  the 
information derived from data and a priori knowledge on parameters. 
Let   be  the  matrix  of  the  observed  data,  in  which  each  row  contains,  for  example,  scores 
belonging to a single subject at different times (   ,  ∈ [1,…, ],  = 1,…, ).     is the unknown 
but  potentially  observable  matrix  of  future  outcomes.  Let    be  the  vector  of  unobserved 
parameters  of  interest,  where   =   ,  , with   =  population  parameters  and   =  variance-
covariance matrix for between-subject variability. . 
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In order to make inferences about   given a realization of the process,  , a model providing a 
joint probability distribution for   and   is needed: 
 
     ,   =        |    [4.1] 
 
where the joint probability density function is given by the 'Bayes rule': it is the product of two 
densities referred to as 'prior distribution',     , and 'likelihood distribution',    |  . The prior 
distribution reflects the a priori expectations about the parameters before seeing the data), while 
the likelihood quantifies the probability that the data are generated by that set of parameters.  
The inference on parameters is provided by their 'posterior distribution', that is the probability 
distribution of the unknown parameters conditioned on the observed realization: 
 
     |   =
   ,  
     =
       |  
       [4.2] 
 
Here,  it  is  possible  to  omit      (which  does  not  depend  on  )  and  rewrite  the  posterior 
distribution as:  
 
     |   ∝        |    [4.3] 
 
A similar objective is to make inferences about future potentially observable outcomes    , after a 
single realization of the process,  , is available. Before the data   are considered, the distribution 
of the unknown but observable   is:  
 
       =     ,     =         |      [4.4] 
 
which  is  the  marginal  distribution  of   ,also  referred  to  as  the  'prior  predictive  distribution', 
reflecting  the  a  priori  expectation  on  the  outcome.  Once  the  data  have  been  observed,  the 
unknown observable outcome     can be predicted from the same process. The distribution of     
given   is called the 'posterior predictive distribution': 
 
           =       ,       =         ,     |     =             |      [4.5] 
 
and is given by an average of conditional predictions,         , over the posterior distribution 
of  . 69 
 
The inference just introduced on     (in the form of [4.5]), can be used to assess model adequacy. 
In  fact,  let  consider   a  specific  statistic  on the  data,  i.e.  a function  from  data  space to  real 
numbers.  As  suggested  by  Gelman  [45],  the  ‘posterior  predictive  check’  consists  in  the 
comparison  between  the  observed  value  of      and the  distribution  of        induced  by  the 
posterior predictive distribution [4.5]. This comparison provides a measure of the plausibility of 
the realization  .  
Let consider now to repeat   times the experiment that produced the current data   using the 
same model,  , and the same unknown value of  . Let   
   ,  = 1,…,  be the set of replicated 
data. The desired posterior distribution [4.5] can be therefore approximated with the distribution 
obtained by   
   ,  = 1,…, . 
 
                                                                                              
                                                                                     
                                                                
                       
        
                                                            
                       
     
                                                                     ⋮                            ⋮           reference distribution 
                                                                
                       
     
 
 
In practice, the posterior distribution of     is obtained through simulation of new data using the 
model,  .  Because   is  unknown,  but  assumed  to  have  the  same  value  that  generated  , 
simulations can be done using draws from its posterior distribution given  ,    |  . Finally, the 
observed statistic,     , can be compared to the reference distribution obtained computing   for 
each replicated dataset. 
In a non Bayesian context, the posterior distribution for the parameters,    |  , is not provided 
by  the  estimation  method:  in  such  cases  an  approximation  to  this  distribution  is  needed.  In 
particular, since a maximum likelihood (ML) approach is adopted for the estimation step (see 
Chapter 2), the approximation is based on the ML estimate    . Then the ‘degenerate distribution’ 
  =     with probability equal to 1 is used to simulate new datasets. 
 
 
4.3. Stochastic simulations 
 
Once  each  different  sub-model  (awake,  stage1,  stage2,  sws  and  rem)  is  identified  using  the 
maximum likelihood approach implemented in NONMEM VI, a set of population parameters, 
including both typical parameters ( ) and inter-individual variance-covariance (Ω), is available 
for the simulation step, to be repeated n times (n is chosen equal to 100).  . 
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The aim of this procedure is to generate from the developed model and its estimated parameters a 
new dataset composed by the polysomnogram outcome for M = 116 (as in the observed dataset) 
new patients. A model that includes all the 5 sub-models is therefore needed in order to produce a 
new sequence of sleep stages for each potential patient. This model is written for NONMEM VI 
and its code is presented in Appendix A. The code can be summarized through the following 
procedure: 
 
1.  The AW state is assumed at the beginning of the night for subject i:    = AW for t = 1 
epoch, and the starting state k is equal to AW. 
2.  t is increased by 1 and a k-sub-model, sm, is chosen according to k value (sm = awake if k 
= AW, stage1 if k = ST1, stage2 if k = ST2, sws if k = SWS, rem if k = REM,) 
3.  The transition probabilities at time t are simulated through the sub-model sm: the ML 
estimates obtained from the estimation step on sub-model sm are used to sample and re-
construct  the  individual  logits  at  time  t  and  thereafter  the  corresponding  individual 
transition probabilities (pAW, pST1, pST2, pSWS and pREM).  
4.  The 5 transition probabilities are placed side by side in a probability scale ranging from 0 
to 1, as shown in Figure 4.1 on the x-axis. 
5.  A random variable, called R, is drawn from a uniform distribution in [0, 1]. 
6.  On the basis of the position of R in the probability scale of Figure 4.1, one of the 5 
possible transitions is supposed to occur: if, for example, R falls into the pST1 interval as 
shown in Figure 4.1, the transition to ST1 is then assumed:       = 1, m = ST1, and, 
having consequently     = ST1. 
7.  Variables providing stage times for each sleep stage and initial sleeplessness length (if a 
non-awake state has already occurred) are updated according to the value of    . 
8.  k assumes     value. 
9.  Steps 2 to 8 are repeated until t = 960 epochs. 
10. Steps 1 to 9 are repeated for i in [1, …, M]. 
 
  
Figure 4.1: Sampling for a multinomial variable with probability vector [pAW, pST1, pST2, pSWS,  pREM].  
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4.3.1. Dataset for simulation 
A brief explanation of the datasets used as input files for the simulation model is provided below. 
Each  dataset  (real  and  simulated)  is  initially  formed  by  four  columns  indicating  the  subject 
identification number (ID), the PSG recording visit (Visit), the night time expressed in epochs 
(Time) and the corresponding sleep stage (STAGE), taking values in {0, 1, 2, 3, 5}   0  for  AW,  1 
for ST1, 2 for ST2, 3 for SWS, 5 for REM . Each column length is therefore M x N = 116 x 960. 
 
ID  Visit  Time  STAGE 
1  3  1  0 
1  3  2  0 
1  3  3  1 
⋮  ⋮  ⋮  ⋮ 
1  3  960  3 
2  3  1  0 
⋮  ⋮  ⋮  ⋮ 
 
 
Five  more  columns  called  MDV0,  MDV1,  MDV2,  MDV3  and  MDV5  (‘MDV’  stands  for 
‘missing data value’), indicating whether the previous stage is 0, 1, 2, 3, 5 or not, are added to the 
dataset.  For  example,  MDV0  is  equal  to  0  if  the  previous  state  is  AW,  and  1  otherwise. 
Furthermore, five binary columns called AW, ST1, ST2, ST3 and REM are added for indicating if 
the current state is 0, 1, 2, 3 or 5, respectively. For example, AW is equal to 1 if the current state 
is AW, and 0 otherwise. 
 
ID  Time  STAGE  MDV0  MDV1  …  MDV5  AW  ST1  …  REM  STT  SL  IS 
1  1  0  1  1    1  1  0    0  0  0  4 
1  2  0  0  1  …  1  1  0  …  0  1  0  4 
1  3  1  0  1    1  0  1    0  2  1  4 
1  4  0  1  0    1  1  0    0  1  1  4 
⋮    ⋮            ⋮          ⋮ 
2  1  0  1  1    1  1  0    0  0  0  30 
 
 
These columns are useful during the estimation step for extracting relevant data for each single 
sub-model,  and  during  the  validation  process  for  easily  computing  the  statistics  of  interest. 
Furthermore, a column counting for the individual stage time (the number of epochs since the last 
transition) is added and called STT. Finally, due to the introduction of the Initial Sleeplessness 
feature  for the awake sub-model,  two  more columns  are  needed:  a  binary  column  called  SL . 
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(’sleep’), which is 1 from the epoch of first non-awake state up to the last epoch for each subject, 
and one called IS (’Initial Sleeplessness’), that reports the number of awake epochs before the 
first episode of non-awake (IS including also the first non-awake epoch). 
 
 
4.4. Posterior predictive check (PPC) 
 
The model performance in the prediction of the aggregated parameters (WASO, LPS, etc) was 
tested  through  the  implementation  of  the  'posterior  predictive  check'  (PPC).  Since  these 
parameters (or at least some of them) are usually considered as the ‘efficacy endpoints’ of clinical 
studies aimed to test efficacy of hypnotic drugs, this term will also be used as synonymous of 
‘aggregated parameters’. 
The individual values for each of these parameters, derived from the observed data, are compared 
to  the  corresponding  values  computed  from  the  simulated  data.  In  particular,  considering  a 
specific endpoint, the median of the individual values is computed in each dataset (observed or 
simulated) and the relative deviations of medians is calculated as follows: 
 
                  =
                                              
                      
. 
 
For each endpoint, the distribution of relative deviations is computed and plotted in a box-whisker 
plot (Figure 4.2) using the R package (R 2.10.0 from the R Development Core, 2009). If the 
model is adequate, relative deviations need to be distributed around the zero line. 
The parameters of interest represented in Figure 4.2 are the following: Latency to Persistent Sleep 
(LPS), Wake After Sleep Onset (WASO), Total Sleep Time (TST), time spent in each stage 
(tAW, tST1, tST2, tSWS, tREM), time spent in non-REM sleep (tNREM), sleep efficiency in 0-2 
hours of bed time (SE1), 2-4 hours of bed time (SE2), 4-6 hours of bed time (SE3), 6-8 hours of 
bed time (SE4), mean extension of each sleep stage (meanAW, meanST1, meanST2, meanSWS, 
meanREM),  number of transitions to each stage (nAW, nST1, nST2, nSWS, nREM). 
 
4.4.1. PPC results 
Posterior predictive check indicates a good agreement between simulated and observed efficacy 
endpoints in most cases (Fig. 4.2). Only 1 out of 23 median aggregated parameters computed 
from the real study fall outside the range of the median values computed from the simulated 
studies: this parameter is the time spent in SWS (tSWS), which is under-predicted. Figure 4.3 
shows the histogram of the relative deviations for the simulated tSWS medians, together with the 73 
 
corresponding  density  function  (darkgreen  line)  and  confidence  interval  (red  dashed  lines) 
computed as in the box-whisker plots, i.e.: 
 
[Q1 – 1.5 * (Q3-Q1), Q3 + 1.5 * (Q3-Q1)], 
 
where Q1 and Q3 are the first and the third quartile of the distribution, respectively. It is notable 
to observe that the zero relative deviation (vertical black line) falls outside the latter confidence 
interval. This bias is probably due to the low frequency of appearance of SWS during the night, 
and the consequent low number of observations available for the transitions from this sleep stage. 
Other PPC plots were produced considering statistics different from the median: they are not 
reported  in  this  thesis  but  they  were  all  considered  relevant  in  judging  the  model  predictive 
performance, in terms of both typical outcomes and variability extent in the population. 
The PPC outcome presented here can be compared with the one presented in [2], where the 
Markov model with multinomial logistic functions is introduced but not fully implemented with 
all the new features presented in Chapter 3. Although, the aim of this thesis is not related to the 
model development, it is worth to mention that the PPC for the revised model shows a general 
improvement  in  the  predictive  performance  on  the  aggregated  parameters.  In  particular,  a 
significant improvement in LPS and nAW predictions is obtained, which can be associated to the 
introduction of the ‘Initial Sleeplessness’ feature in the awake sub-model. 
In conclusion, an example of the use of PPC has been provided to show how the proposed model 
is suitable to predict aggregated characteristics of PSG data in a patient population. 
 
Figure 4.2: Results from posterior predictive check: distributions of the relative deviations of median efficacy endpoints 
in 100 simulated clinical studies from the medians in the real study. 
Posterior Predictive Checks on Efficacy Endpoints. 
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Figure 4.3: Distribution of relative deviations of median tSWS in simulated populations from the observed values. 
 
 
4.5. Visual predictive check (VPC)   
 
Since the model was built with the aim to properly describe the sleep internal architecture, it is 
important in the validation process to verify whether the model adequately describes sleep time-
course along the night .  
Visual predictive check (VPC) allows to test model capability to properly describe sleep stage and 
transition frequencies and therefore should be considered complementary to PPC, which mainly 
focus on parameters of clinical interest. 
The concept governing this type of diagnostic method is the one which has been introduced in the 
theory section and applied for PPC: a statistic of interest is compared to a reference distribution 
obtained through simulation. However, in the VPC procedure the statistics under examination 
obtained from both raw and simulated data are evaluated over the independent variable, in this 
case  the  night  time  (the  same  procedure  can  be  repeated  over  stage  time,  but  night  time  is 
considered  more  relevant  for  a  physiological  perspective).  The  observed  statistic  and  the 
corresponding  confidence  interval  derived  from  simulations  are  therefore  plotted  against  the 
independent variable in order to have a ‘visual check’ on the predictive model performance. This 
diagnostic  is  very  helpful  to  evaluate  potential  model  misspecifications  over  the  independent 
variable.  
The VPC implemented in this thesis regards two different statistics evolving with night time and 
obtainable from data:  
 
a)  stage frequencies,     ,  ∀   ∊  , 
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b)  transition frequencies,       ,  ∀  ,  ∊  , 
 
according to Equations 3.1 and 3.2 in paragraph 3.1, respectively.  
The 8-hour night time is divided into 10 intervals of equal width (48 minutes) and both transition 
and stage frequencies are computed on each of them. The choice of 10 intervals is based on two 
key features: to adequately follow sleep physiological variations across the night and to include a 
significant amount of data in each interval for computing confident frequencies.  
VPC implementation was performed using the R package and some relevant code is presented in 
Appendix B.A brief explanation of this code is presented below. 
Let’s consider a specific dataset as presented in paragraph 4.2.1. The number of subjects in each 
stage is calculated for each epoch of the night: a summary dataset is created merging a ‘Time’ 
column (from 1 to 960) to the ‘AW’, ‘ST1’, ‘ST2’, ‘SWS’ and ‘REM’ columns, indicating the 
number of subjects in each of the sleep stages in each epoch.  The number of transitions relative 
to each couple of sleep stages is also calculated over all the subjects at each epoch. As a result, 25 
more columns are added to the summary dataset (‘TRaw1’, for example, indicates the number of 
subjects transitioning from AW to ST1 at every single epoch). 
 
Time  AW  ST1  ST2  …  TRawaw  TRaw1  TRaw2  …  TRR3  TRRR 
1  116  0  0  …  114  1  1  …  0  0 
2  114  1  1  …  112  0  0  …  0  0 
⋮                     
959  44  17  36  …  2  0  …  …  0  0 
960  49  14  34  …  2  0  …  …  0  0 
 
The  ‘Time’  column  is  thereafter  divided  into  10  parts  of  equal  length  and  all  variables  are 
summed together in correspondence to each interval. In this way, the number of transitions from k 
to m and the number of occurrence of k (∀  ,  ∊  ) are computed on the 10 night time intervals 
together with the final statistics (median and 95% confidence interval). 
 
4.5.1. VPC: results 
Figure 4.4 shows the results for the visual predictive check implemented on stage frequencies,     . 
The plots show a general good agreement between the observed and the simulated statistics: the 
observed profiles computed on the 48-minute intervals of the night (red solid lines) fall within the 
confidence  intervals  (C.I.)  obtained  from  the  simulations  (light  blue  areas)  with  very  few 
exceptions (outliers). Both in the observed and simulated data, ST2 is the predominant stage all 
night long except for the first ~50 minutes; ST1, being a transitional state, covers a minimal part 
of the night; SWS mostly occurs between the second hour and the fourth hour, while it almost . 
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disappears afterwards; REM sleep mainly occurs in the second half of the night; AW is strongly 
predominant in the first ~50 minutes and slightly regain importance in the last hours. 
 
Figure 4.4: Results from visual predictive check on stage frequencies. 
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Figures 4.5, 4.6, 4.7, 4.8, 4.9 illustrate the predictive performance of the Markov-chain model 
with respect to the transition frequencies,       , for the transitions from AW, ST1, ST2, SWS and 
REM respectively. A very good match is obtained between observed and simulated frequencies 
for  all the sub-models: the  observed  frequencies  (red  solid  lines) fall  outside  their  simulated 
confidence interval (light blue areas) in very few occasions. 
It is interesting to note the width of the confidence intervals. The transition frequencies from ST2 
are those with the narrowest confidence intervals: in fact, a great amount of data is available for 
estimating  transition  probabilities  from  ST2.  The  awake,  stage1  and  stage2  sub-models  are 
characterized by confidence intervals with approximately constant width, while the sws and rem 
sub-models present time-dependent confidence intervals. This is in agreement with the observed 
predominance of SWS in the first part of the night and of REM sleep in the second one: where 
data  are  more  sparse  a  higher  degree  of  uncertainty  is  shown, resulting  in  larger  confidence 
intervals. 
The plots also confirm that fixing some of the transition probabilities to zero in the model was an 
appropriate choice: in fact, their observed values (red solid lines) are actually very close to zero 
during the whole night time period.  
In  conclusion,  the  model  seems  appropriate  to  describe  the  physiological  evolution  of  the 
considered sleep transitions along the night and VPC confirms to be a valuable tool for checking 
model adequacy to the observed process in its temporal domain. 
 
 
 
 . 
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Figure 4.5: Results from visual predictive check on frequency of transitions from the AW state. 
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Figure 4.6: Results from visual predictive check on frequency of transitions from the ST1 state. 
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Figure 4.7: Results from visual predictive check on frequency of transitions from the ST2 state. 
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Figure 4.8: Results from visual predictive check on frequency of transitions from the SWS state. 
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Figure 4.9: Results from visual predictive check on frequency of transitions from the REM state. 
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4.6. Visual estimation check (VEC) 
 
Visual  estimation  check  (VEC)  is  introduced  in  this  thesis  for  the  purpose  to  analyze  the 
estimation of temporal profiles of typical and individual transition probabilities: profiles estimated 
from  raw  data  are  compared  with  the  corresponding  profiles  estimated  from  the  simulated 
datasets. 
Differently from VPC where some statistics on the simulated datasets   
    are produced, the 
simulated data are used for re-estimating the same Markov model, thus obtaining new estimates 
of the parameters, called   . This method has been already proposed as a validation approach 
where  the  distribution  of      is  compared  with  the  original  set  of     [6,7].  The  further 
implementation of this method proposed in this thesis is to transform the estimated parameters in 
the form of transition probabilities. In this way, we can still use a visual approach for the model 
validation (as in PPC and VPC) based on a meaningful parameters representation, as the transition 
probabilities are.  
 
 
 
 
 
 
 
 
An automatic procedure is implemented for identifying each of the 5 sub-models on all the 100 
simulated datasets. Five different summary datasheets are created by this procedure, in which 
population and inter-subject variability parameters are obtained for a specific sub-model using 
NONMEM software. In our case population parameters include the values of the typical logits at 
the night time break-points, the values of the stage time effects and the values for the internal 
break-points  of  night  time  and  stage  time.  Between  subject  variability  is  estimated  from 
covariance matrix and represents the individual deviations from the typical logits.         
The transition probability profiles are then computed from the estimated parameters. In particular, 
the  typical  logit  profiles  for  each  sub-model  are  re-built  from  the  population  estimates.  The 
individual deviations from the typical logits are drawn from Gaussian distributions with zero 
mean and covariance matrix estimated from the specific sub-model. Both typical and individual 
transition  probability  profiles  are  then  computed  according  to  Equation  3.8  from  typical  and 
individual  logit  profiles.  The  5
th  and  95
th  percentiles  of  the  individual  transition  probability 
profiles are therefore computed. Such procedure is followed for the original and all the simulated 
SIMULATION 
of n=100 datasets,   
   ,  
from the previously 
estimated parameters 
  =   ,Ω  
RE-ESTIMATION 
of the model parameters 
for each simulated dataset 
   =    ,Ω   
COMPUTATION 
of the transition 
probabilities profiles from 
the estimated parameters 
of each dataset . 
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datasets,  producing  an  observed  and  n  =  100  simulated  profiles  for  the  typical  transition 
probabilities and the 5
th and 95
th percentiles on the BSV. The 95% confidence intervals for each 
of them are therefore computed from the simulated profiles. 
Since this procedure implies computational burden it was applied only to the final model. 
 
 
4.6.1. VEC: results 
Figures 4.10, 4.11, 4.12, 4.13 and 4.14 illustrate the results from VEC performed on transition 
probabilities, for the transitions from AW, ST1, ST2, SWS and REM respectively. The black 
solid line represents the typical transition probability estimated from raw data and the pink area 
corresponds to the 95% confidence interval (C.I.) on the typical transition probability as derived 
from  simulations.  The  dashed  black  lines  represent  the  5
th  and  95
th  percentiles  of  the  inter-
individual distribution and the blue area their 95% confidence intervals. Mixed color (violet) areas 
come  from  the  superimposition  of  pink  and  blue  confidence  intervals  (note  that  there  is 
superimposition on the typical and 5
th and/or 95
th confidence intervals for the awake, sws and rem 
sub-models). 
In general, a good agreement between profiles estimated from raw and simulated data is shown in 
these plots, with exception for the transitions from REM to ST2 and from REM to REM at the 
beginning of the night. Even though the observations of REM sleep in the first part of the night 
are  almost  absent  (see  Fig.  4.4),  it  is  difficult  to  understand  for  which  reason  the  transition 
probabilities  estimated  from  observed  data  are  different  from  the  transition  probabilities  re-
estimated from simulated data. One possible explanation is related to the estimation method in 
presence of shrinkage effect. In fact, the Laplacian method is less robust when high ‘η-shrinkage’ 
is revealed [3]. A full description of the “shrinkage phenomena” was not an objective of this 
thesis and detailed information can be found in literature [46]. 
In nonlinear mixed-effect modeling, the estimated individual deviations from a typical parameter 
value  are  called  ‘Empirical  Bayes  Estimates’  (EBEs)  as  described  in  Chapter  2.  EBEs  of  a 
specific inter-individual random effect η are used for computing η-shrinkage as follows: 
 
1 – (SD (EBEs))/ω, 
 
where ω is the population model estimate of the SD in η.  
In case of shrinkage the EBEs are biased and therefore the Laplace estimation method can suffer 
from  this  effect.  According  to  literature  [46]  η-shrinkage  higher  than  ~25%,  is  considered 
relevant. 85 
 
The stage transitions mostly affected by shrinkage in the proposed Markov-chain model are those 
leaving SWS and REM sleep (see Table 4.1): η-shrinkage results ~50% for the logit value defined 
on the ratio between the probability of moving from SWS to ST1 sleep and the probability of 
staying in SWS, and > 25% for the logit value defined on the ratio between the probability of 
staying in REM sleep and the probability of moving to SWS.  
 
Sub-model\logit  logit1  logit2  logit3  logit4 
awake  0.17  0.14  0.23  . 
stage1  0.17  0.10  0.18  . 
stage2  0.17  0.10  0.08  0.28 
sws  .  0.49  0.12  . 
rem  0.15  0.14  0.27  . 
 
Table 4.1: η-shrinkage values for all the sub-models. 
 
Consequently, the only case in which high η-shrinkage could be considered a potential issue in the 
Laplacian method is the transition from REM to ST2 sleep. However, other high η-shrinkage 
effect as in the SWS stage did not result in any bias on VEC . 
It  is  interesting  to  note  that  also  the  amplitude  of  confidence  intervals  on  the  transition 
probabilities  is  related  to  the  amount  of  available  information:  where  data  are  sparser  their 
amplitude is larger. This can be seen for transitions of sws and rem sub-models: they show very 
similar time-dependency between amplitude of confidence intervals and amount of SWS and 
REM observations; moreover, their confidence interval width is higher, for example, than that 
computed for stage2 sub-model, for which observations are much more abundant. 
Furthermore, it is interesting to notice that confidence intervals in proximity of probability equal 
to 0 or 1 are generally narrower than those in proximity of probability = 0.5 (see, for example, the 
transitions from ST2 to ST1 or from SWS to ST2). This is due to the non-linear behavior of the 
logit transformation implemented in the model: an interval in the logit scale (-∞, +∞) will be 
squashed in the probability scale [0, 1]. Therefore larger C.I. will appear in case of logit values 
near zero, while narrower C.I. will be present with logit values belonging to the higher and lower 
parts of the (-∞, +∞)  interval. 
Concluding,  the  performed  VEC  allows  to  state  once  more  that  the  model  is  suitable  for 
describing the available sleep data, but also that the adopted estimation method is robust enough 
for estimating such model. VEC shows to be an appealing and meaningful visual diagnostics to 
apply with models on categorical data (but not only) and to put side by side to other indicators of 
potential estimator inadequacy (like the η-shrinkage computation). 
 . 
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Figure 4.10: Results from visual estimation check on transitions from the AW state. 
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Figure 4.11: Results from visual estimation check on transitions from the ST1 state. 
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Figure 4.12: Results from visual estimation checks on transitions from the ST2 state. 
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Figure 4.13: Results from visual estimation checks on transitions from the SWS state. 
P
r
o
b
a
b
i
l
i
t
y
P
r
o
b
a
b
i
l
i
t
y
From SWS to SWS From SWS to ST2
From SWS to AW
Time [hours] Time [hours]
Time [hours] Time [hours]
Time [hours]
P
r
o
b
a
b
i
l
i
t
y
From SWS to REM
From SWS to ST1. 
 
90             
 
 
Figure 4.14: Results from visual estimation checks on transitions from the REM state. 
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4.7.  Conclusions 
 
In this Chapter different diagnostic methods were proposed to investigate the adequacy and the 
performance  of the  proposed Multinomial Markov-chain  model [2]  for  describing  sleep  data. 
Firstly,  diagnostic  methods  based  on  stochastic  simulation  were  implemented  to  assess  the 
capacity of the model to describe some important characteristics of the polysomnograpghic (PSG) 
data. In particular, ‘Posterior Predictive Check’ on the aggregated parameters (WASO, etc) and 
‘Visual Predictive Check’ on the transition frequencies and the frequencies of occurrence of each 
stage were implemented. The results from both these methodologies showed that the proposed 
model is sufficiently robust for describing these data characteristics and the dynamic behaviour of 
the sleep process. 
However, bias and imprecision in the desired predictions may also depend on weaknesses in the 
estimation methods. Therefore, A new diagnostic method derived by a recently proposed [6,7] 
approach for checking both model and estimation method performance has been introduced: the 
‘Stochastic Simulations followed by Estimation’ (SSE) based diagnostics. The peculiarity of the 
method based on SSE as implemented in this thesis is that it allowed to perform a visual check on 
the characteristics of interest: in particular, the transition probabilities between sleep stages. This 
kind of visual comparison – applied for the first time in categorical models - has been called 
‘Visual  Estimation  Check’  (VEC).  The  results  from  the  implementation  of  such  diagnostic 
corroborated the adequacy of the multinomial Markov-Chain model to describe sleep architecture 
and provided a valuable tool to evaluate the goodness of the proposed estimation method.  
 
 
 
 
 
 
 . 
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Discussion and Final Remarks 
   
 
 
Polysomnography is a key measurement to objectively assess and properly diagnose different 
types  of  sleep  disorders. Currently, the  clinical  use  of polysomnography  is mainly  related  to 
assess sleep aggregated characteristics (WASO, LPS, etc.). However, there is growing evidence 
suggesting that the maintenance of the sleep architecture is one of the critical aspects for sleep 
quality.  
Clearly, mathematical models can be of great help when trying to quantify complex physiological 
processes and a Multinomial Mixed-Effect Markov-chain model approach has been proposed in 
this thesis to properly quantify the sleep architecture considered as a time-course pattern among 
specific sleep stages.  
The aim of this thesis was therefore to evaluate the appropriateness of such Markov-chain model. 
The application of this model, in fact, is considered a valuable methodology for the analysis and 
interpretation of clinical studies in the insomnia indication and a proper evaluation of model 
performances was therefore considered of particular importance.  
The  analysis  conducted  in  this  work  was  focused,  in  particular,  on  the  evaluation  of  model 
performances in predicting both the sleep aggregated parameters (LPS, WASO, etc.) used in the 
clinical practice to quantify the severity of sleep disorders and the sleep physiological pattern, 
whose maintenance has been demonstrated to be critical. It is worth mentioning that the novel 
mechanisms in the treatment of sleep disorders are aimed to reduce sleep onset and increase sleep 
maintenance preserving the physiological sleep architecture.  
In addition, the ability of this model to properly describe the time-course of sleep can be a very 
helpful tool for clinical trial simulations, where the effect of different doses and treatment periods 
can be predicted. 
Three different diagnostic methodologies have been presented and implemented in this thesis for 
checking the adequacy of the proposed model: the ‘Posterior Predictive Check’(PPC) and the 
‘Visual  Predictive  Check’(VPC)  based  on  stochastic  simulation  and  the  ‘Visual  Estimation 
Check’(VEC),  introduced  with  this  thesis,  derived  by  the  ‘stochastic  simulation  followed  by 
estimation’ (SSE) method. Such methodologies provided evidence of the good properties of the 
proposed Markov-chain model and their implementation in this thesis illustrates their usefulness 
for  checking  model  adequacy.  In  particular,  the  PPC  was  demonstrated  to  be  an  important 
simulation-based  diagnostic  showing  that  the  proposed  model  is  suitable  for  predicting  the 
aggregated  characteristics  of  PSG  data  in  a  population  of  subjects.  Furthermore,  through  the 
implementation  of  the  VPCs  on  the  transition  frequencies  and  the  stages  frequencies  of . 
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occurrence,  the  model  was  demonstrated  to  be  appropriate  for  describing  the  physiological 
evolution of the considered statistics along the night. The VPC method therefore confirms to be a 
good  tool  for  checking  model  adherence  to  the  observed  data  and  to  the  process  temporal 
dynamics. Finally, the results from the performed VEC allow to state once more that the model is 
suitable for describing the available sleep data, but also that the adopted estimation method is 
robust  enough.  Such  diagnostics  allow  the  evaluation  of  both  model  and  estimation  method 
performances in an easily understandable visual form. To my knowledge, this work is the first to 
implement the SSE in this way. The implemented VEC seems to be an appealing and meaningful 
visual diagnostics to apply with models on categorical data (but not only) and to put side by side 
to other indicators of potential estimator inadequacy (like the η-shrinkage computation).  
In  summary,  the  validation  proposed  in  this thesis indicates that  the  proposed  model  can  be 
considered a robust modeling framework for describing and predicting sleep architecture. This 
analysis has been conducted on data from a population of insomniac patients treated with placebo, 
but  the  natural  future  development  will  be  to  extend  this  model  (and  the  related  validation 
approach) to include the terms related to the drug effect to allow simulating complete clinical 
trials.  95 
 
Appendix A 
NONMEM code 
   
 
A.1. ‘Awake sub-model’ 
 
 
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;; 
; AWAKE sub-model 
; NONMEM model file for the transition from awake 
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;; 
 
$PROB trAW 
 
$INPUT ID VIS TIME DV=STAG MDV0 MDV1 MDV2 MDV3 MDV5 MDV 
       DROP DROP DROP DROP DROP STT EVID BPS0 DROP DROP DROP DROP MED  
       DROP DROP DROP DROP SL DROP IS MIS 
 
  ; TIME = epoch number (between 1 and 960) 
  ; STT = stage_time (number of epochs)  
  ; BPS0 = max_stage time observed in the data 
  ; MED = median_stage time observed in the data 
  ; SL = 0 if first sleep stage has not occurred yet, 1 otherwise 
  ; IS = first epoch with SL==1 
  ; MIS = maximum Initial Sleeplessness observed in the data 
   
 
$DATA tr0Visit33MAD103894forNONMEMallTimes34tSTevidSLIS.csv IGNORE=@ 
   
  IGNORE=(MDV0.EQ.1) 
  IGNORE=(STAG.GT.5) 
  IGNORE=(STAG.EQ.3) 
 
  ;dataset contains only observations immediately preceded by awake 
   stage 
 
$PRED                   
   
  TVG1A=THETA(1) 
  TVG2A=THETA(2) 
  TVG3A=THETA(3) 
  TVG1B=THETA(4) 
  TVG2B=THETA(5) 
  TVG3B=THETA(6) 
  TVG1C=THETA(7) 
  TVG2C=THETA(8) 
  TVG3C=THETA(9) 
 
  STE1b=THETA(10) 
  STE2b=THETA(11) 
  STE3b=THETA(12) . 
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  STE1c=THETA(13) 
  STE2c=THETA(14) 
  STE3c=THETA(15) 
 
  BPA=IS 
  BPC=960 
  BPB=(BPC-BPA)*THETA(16)+BPA 
 
  BPsa=1 
  BPsc=BPS0 
  BPsb=(BPsc-BPsa)*THETA(17)+BPsa 
  
  BP1=2 
  BP3=MIS    ;MAX initial sleeplessness (max(IS)-1)  
  BP2=(BP3-BP1)*THETA(18)+BP1 
 
 
  TVG11=THETA(19) 
  TVG21=THETA(20) 
  TVG31=THETA(21) 
  TVG12=THETA(22) 
  TVG22=THETA(23) 
  TVG32=THETA(24) 
  TVG13=THETA(25) 
  TVG23=THETA(26) 
  TVG33=THETA(27) 
 
;-------------------------------- 
; stage_time effect interpolation 
;-------------------------------- 
 
  IF (STT.LE.BPsb.AND.SL.EQ.1) THEN 
    G1A=(TVG1A+ETA(1))*(BPsb-STT)/(BPsb-BPsa)+(TVG1A+ETA(1)+STE1b)*(STT- 
BPsa)/(BPsb-BPsa) 
    G2A=(TVG2A+ETA(2))*(BPsb-STT)/(BPsb-BPsa)+(TVG2A+ETA(2)+STE2b)*(STT-
BPsa)/(BPsb-BPsa) 
    G3A=(TVG3A+ETA(3))*(BPsb-STT)/(BPsb-BPsa)+(TVG3A+ETA(3)+STE3b)*(STT-
BPsa)/(BPsb-BPsa) 
 
    G1B=(TVG1B+ETA(1))*(BPsb-STT)/(BPsb-BPsa)+(TVG1B+ETA(1)+STE1b)*(STT-
BPsa)/(BPsb-BPsa) 
    G2B=(TVG2B+ETA(2))*(BPsb-STT)/(BPsb-BPsa)+(TVG2B+ETA(2)+STE2b)*(STT-
BPsa)/(BPsb-BPsa) 
    G3B=(TVG3B+ETA(3))*(BPsb-STT)/(BPsb-BPsa)+(TVG3B+ETA(3)+STE3b)*(STT-
BPsa)/(BPsb-BPsa) 
 
    G1C=(TVG1C+ETA(1))*(BPsb-STT)/(BPsb-BPsa)+(TVG1C+ETA(1)+STE1b)*(STT-
BPsa)/(BPsb-BPsa) 
    G2C=(TVG2C+ETA(2))*(BPsb-STT)/(BPsb-BPsa)+(TVG2C+ETA(2)+STE2b)*(STT-
BPsa)/(BPsb-BPsa) 
    G3C=(TVG3C+ETA(3))*(BPsb-STT)/(BPsb-BPsa)+(TVG3C+ETA(3)+STE3b)*(STT-
BPsa)/(BPsb-BPsa) 
  ENDIF 
 
  IF (STT.GT.BPsb.AND.SL.EQ.1) THEN 
    G1A=(TVG1A+ETA(1)+STE1b)*(BPsc-STT)/(BPsc-BPsb)+(TVG1A+ETA(1)+STE1c) 
*(STT-BPsb)/(BPsc-BPsb) 
    G2A=(TVG2A+ETA(2)+STE2b)*(BPsc-STT)/(BPsc-BPsb)+(TVG2A+ETA(2)+STE2c) 
*(STT-BPsb)/(BPsc-BPsb) 
    G3A=(TVG3A+ETA(3)+STE3b)*(BPsc-STT)/(BPsc-BPsb)+(TVG3A+ETA(3)+STE3c) 
*(STT-BPsb)/(BPsc-BPsb) 97 
 
 
    G1B=(TVG1B+ETA(1)+STE1b)*(BPsc-STT)/(BPsc-BPsb)+(TVG1B+ETA(1)+STE1c) 
*(STT-BPsb)/(BPsc-BPsb) 
    G2B=(TVG2B+ETA(2)+STE2b)*(BPsc-STT)/(BPsc-BPsb)+(TVG2B+ETA(2)+STE2c) 
*(STT-BPsb)/(BPsc-BPsb) 
    G3B=(TVG3B+ETA(3)+STE3b)*(BPsc-STT)/(BPsc-BPsb)+(TVG3B+ETA(3)+STE3c) 
*(STT-BPsb)/(BPsc-BPsb) 
 
    G1C=(TVG1C+ETA(1)+STE1b)*(BPsc-STT)/(BPsc-BPsb)+(TVG1C+ETA(1)+STE1c) 
*(STT-BPsb)/(BPsc-BPsb) 
    G2C=(TVG2C+ETA(2)+STE2b)*(BPsc-STT)/(BPsc-BPsb)+(TVG2C+ETA(2)+STE2c) 
*(STT-BPsb)/(BPsc-BPsb) 
    G3C=(TVG3C+ETA(3)+STE3b)*(BPsc-STT)/(BPsc-BPsb)+(TVG3C+ETA(3)+STE3c) 
*(STT-BPsb)/(BPsc-BPsb) 
  ENDIF 
 
;-------------------------------- 
; logits interpolation before IS 
;-------------------------------- 
 
  IF (TIME.GE.BP1.AND.TIME.LE.BP2.AND.SL.EQ.0) THEN 
     
    ; individual logits 
    G1=(TVG11+ETA(4))*(BP2-TIME)/(BP2-BP1)+(TVG12+ETA(4))*(TIME-
BP1)/(BP2-BP1) 
    G2=(TVG21+ETA(5))*(BP2-TIME)/(BP2-BP1)+(TVG22+ETA(5))*(TIME-
BP1)/(BP2-BP1) 
    G3=(TVG31+ETA(6))*(BP2-TIME)/(BP2-BP1)+(TVG32+ETA(6))*(TIME-
BP1)/(BP2-BP1) 
 
    ; population logits 
    G1p=TVG11*(BP2-TIME)/(BP2-BP1)+TVG12*(TIME-BP1)/(BP2-BP1) 
    G2p=TVG21*(BP2-TIME)/(BP2-BP1)+TVG22*(TIME-BP1)/(BP2-BP1) 
    G3p=TVG31*(BP2-TIME)/(BP2-BP1)+TVG32*(TIME-BP1)/(BP2-BP1) 
  ENDIF 
 
  IF (TIME.GT.BP2.AND.TIME.LE.BP3.AND.SL.EQ.0) THEN 
     
   ; individual logits 
   G1=(TVG12+ETA(4))*(BP3-TIME)/(BP3-BP2)+(TVG13+ETA(4))*(TIME-
BP2)/(BP3-BP2) 
    G2=(TVG22+ETA(5))*(BP3-TIME)/(BP3-BP2)+(TVG23+ETA(5))*(TIME-
BP2)/(BP3-BP2) 
    G3=(TVG32+ETA(6))*(BP3-TIME)/(BP3-BP2)+(TVG33+ETA(6))*(TIME-
BP2)/(BP3-BP2) 
 
    ; population logits 
    G1p=TVG12*(BP3-TIME)/(BP3-BP2)+TVG13*(TIME-BP2)/(BP3-BP2) 
    G2p=TVG22*(BP3-TIME)/(BP3-BP2)+TVG23*(TIME-BP2)/(BP3-BP2) 
    G3p=TVG32*(BP3-TIME)/(BP3-BP2)+TVG33*(TIME-BP2)/(BP3-BP2) 
  ENDIF 
 
;-------------------------------- 
; logits interpolation after IS 
;-------------------------------- 
 
  IF (TIME.GE.BPA.AND.TIME.LE.BPB.AND.SL.EQ.1) THEN 
 
    ; individual logits 
    G1=G1A*(BPB-TIME)/(BPB-BPA)+G1B*(TIME-BPA)/(BPB-BPA) 
    G2=G2A*(BPB-TIME)/(BPB-BPA)+G2B*(TIME-BPA)/(BPB-BPA) . 
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    G3=G3A*(BPB-TIME)/(BPB-BPA)+G3B*(TIME-BPA)/(BPB-BPA) 
     
    ; population logits 
    G1p=TVG1A*(BPB-TIME)/(BPB-BPA)+TVG1B*(TIME-BPA)/(BPB-BPA) 
    G2p=TVG2A*(BPB-TIME)/(BPB-BPA)+TVG2B*(TIME-BPA)/(BPB-BPA) 
    G3p=TVG3A*(BPB-TIME)/(BPB-BPA)+TVG3B*(TIME-BPA)/(BPB-BPA) 
  ENDIF 
 
  IF (TIME.GT.BPB.AND.TIME.LE.BPC.AND.SL.EQ.1) THEN 
 
    ; individual logits 
    G1=G1B*(BPC-TIME)/(BPC-BPB)+G1C*(TIME-BPB)/(BPC-BPB) 
    G2=G2B*(BPC-TIME)/(BPC-BPB)+G2C*(TIME-BPB)/(BPC-BPB) 
    G3=G3B*(BPC-TIME)/(BPC-BPB)+G3C*(TIME-BPB)/(BPC-BPB) 
 
    ; population logits 
    G1p=TVG1B*(BPC-TIME)/(BPC-BPB)+TVG1C*(TIME-BPB)/(BPC-BPB) 
    G2p=TVG2B*(BPC-TIME)/(BPC-BPB)+TVG2C*(TIME-BPB)/(BPC-BPB) 
    G3p=TVG3B*(BPC-TIME)/(BPC-BPB)+TVG3C*(TIME-BPB)/(BPC-BPB) 
  ENDIF 
 
  ;----------------------------------------------- 
  ; typical transition probabilities as anti-logit 
  ;----------------------------------------------- 
 
  PAWp=1/(1+EXP(G1p)+EXP(G2p)+EXP(G3p)) 
  P1p=EXP(G1p)/(1+EXP(G1p)+EXP(G2p)+EXP(G3p)) 
  P2p=EXP(G2p)/(1+EXP(G1p)+EXP(G2p)+EXP(G3p)) 
  P3p=0 
  PRp=EXP(G3p)/(1+EXP(G1p)+EXP(G2p)+EXP(G3p)) 
 
  ;-------------------------------------------------- 
  ; individual transition probabilities as anti-logit 
  ;-------------------------------------------------- 
 
  PAW=1/(1+EXP(G1)+EXP(G2)+EXP(G3)) 
  P1=EXP(G1)/(1+EXP(G1)+EXP(G2)+EXP(G3)) 
  P2=EXP(G2)/(1+EXP(G1)+EXP(G2)+EXP(G3)) 
  P3=0 
  PR=EXP(G3)/(1+EXP(G1)+EXP(G2)+EXP(G3)) 
   
  ;-------------------------------- 
  ; likelihood 
  ;-------------------------------- 
 
  Y=0 
  IF (STAG.EQ.0) Y=PAW 
  IF (STAG.EQ.1) Y=P1 
  IF (STAG.EQ.2) Y=P2 
  IF (STAG.EQ.5) Y=PR 
 
  IWRES=1 
 
$THETA                ;LOGIT:1,2,3  BP:A,B,C  BP_TIME:a,b,c 
 
  -1; TVG1A 
  -5; TVG2A 
  -10 FIX ; TVG3A 
 
  -1; TVG1B 
  -1; TVG2B 99 
 
  -4; TVG3B 
 
  -.1; TVG1C 
  -2; TVG2C 
  -2; TVG3C 
 
  -2; STE1b 
  -3; STE2b 
  -5; STE3b 
 
  -5; STE1c 
  -10 FIX; STE2c 
  -10 FIX; STE3c 
 
  (0,.1,1);  REL BPB 
 
  (0,.1,1);  BPsb      
  (0,.4,1);  REL BP2      
 
  -5; TVG11 
  -10 FIX; TVG21 
  -10 FIX; TVG31 
 
  -5; TVG12 
  -5; TVG22 
  -10 FIX; TVG32 
 
  -1; TVG13 
  -10 FIX; TVG23 
  -10 FIX; TVG33 
 
$OMEGA BLOCK(2) 
 
  .1   ;G1i 
  -.02 .5   ;G2i 
 
$OMEGA 
 
  .5  ;G3i 
  0 FIX  ;G1aw 
  0 FIX  ;G2aw 
  0 FIX  ;G3aw 
 
$ESTIMATION METHOD=COND LAPLACE LIKE MSFO=msf1 
 
$COVARIANCE MATRIX=R PRINT=E 
 
$TAB ID VIS TIME STAG 
     ETA(1) ETA(2) ETA(3) 
     PAWp P1p P2p P3p PRp PAW P1 P2 P3 PR PAWpm P1pm P2pm P3pm PRpm 
     ONEHEADER NOPRINT NOAPPEND FILE=sdtab1 
 
$TAB ID ETA(1) ETA(2) ETA(3) 
     ONEHEADER NOPRINT NOAPPEND FILE=patab1 
 
 
 . 
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A.2.’Simulator’ 
 
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;; 
; NONMEM control file for the simulation of new datasets 
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;; 
 
$PROB SHmf_296_292_288_297_290p1_34 
 
$INPUT ID DV=VIS TIME DROP DROP DROP DROP DROP DROP MDV 
       DROP DROP DROP DROP DROP DROP EVID 
   
  ; TIME = epoch number (between 1 and 960)   
 
$DATA treatment0Visit33MAD103894forNONMEMallTimes34tSTevid.csv IGNORE=@ 
 
$ABBREVIATED DERIV2=NO 
 
$PRED                  ;LOGIT:1,2,3  BP:A,B,C  BP_STT:sa,sb,sc 
                       ;STT=stage_time  STE=stage_effect 
  REP=IREP 
 
  AA=THETA(1)+ETA(1)+ETA(2)+ETA(3)+ETA(4)+ETA(5)+ETA(6)+ETA(7)+ETA(8) 
  AA=AA+ETA(9)+ETA(10)+ETA(11)+ETA(12)+ETA(13)+ETA(14)+ETA(15)+ETA(16) 
   
  MDV0=1 
  MDV1=1 
  MDV2=1 
  MDV3=1 
  MDV5=1 
 
  IF (TIME.EQ.1) THEN 
    PST=-1                     ;previous stage 
    PSTT=-10                   ;previous stage time 
    PSL=0                      ;previous sleep 
    SL=0                       ;sleep 
    IS=0                       ;prima epoca con SL==1 
  ENDIF 
   
  SL=0 
  IF (PSL.EQ.0.AND.PST.GT.0) SL=1 
  IF (PSL.EQ.1) SL=1 
  IF (PSL.EQ.0.AND.SL.EQ.1) IS=TIME 
 
  STT=PSTT+1      ; stage_time     
         
  IF (PST.EQ.0) MDV0=0 
  IF (PST.EQ.1) MDV1=0 
  IF (PST.EQ.2) MDV2=0 
  IF (PST.EQ.3) MDV3=0 
  IF (PST.EQ.5) MDV5=0 
 
  ; break-points 
  BPA=2 
  BPB=960 
  BPC=960 
  BPsa=1 
  BP1=1 
  BP2=2 101 
 
  BP3=1 
 
  ; stage_time effect 
  STE4b=1 
  STE4c=1 
   
  ; for stage2 sub-model 
  TVG4A=1 
  TVG4B=1 
  TVG4C=1 
  DEV4=1 
 
  ; for awake sub-model 
  TVG11=1 
  TVG21=1 
  TVG31=1 
  TVG12=1 
  TVG22=1 
  TVG32=1 
  TVG13=1 
  TVG23=1 
  TVG33=1 
    
  ;------------------------------------------------------------- 
  ;  if the current state is AW the awake sub-model is taken 
  ;  into account. 
  ;  Initialization using the previously estimated THETAs 
  ;------------------------------------------------------------- 
 
  IF (MDV0.EQ.0) THEN 
    BPA=IS       ; first epoch with SL==1 
     
     
    BPB=(BPC-BPA)*0.0679+BPA 
    BPsb==(BPsc-BPsa)*0.024+BPsa 
          BPsc=265   ; max stage_time           
 
    BP1=2 
    BP3=371             ;MAX initial sleeplessness  
    BP2=(BP3-BP1)*0.0298+BP1 
 
    STE1b=-2.49 
    STE2b=-3.59 
    STE3b=-5.67 
 
    STE1c=-6.63 
    STE2c=-10 
    STE3c=-10 
 
    TVG1A=-0.251 
    TVG2A=-2.66 
    TVG3A=-10 
    TVG1B=-0.209 
    TVG2B=-1.01 
    TVG3B=-2.86 
    TVG1C=-0.203 
    TVG2C=-2.08 
    TVG3C=-2.1 
 
    TVG11=-5.76 
    TVG21=-10 . 
 
102             
 
    TVG31=-10 
    TVG12=-3.93 
    TVG22=-7.63 
    TVG32=-10 
    TVG13=-4.86 
    TVG23=-10 
    TVG33=-10 
 
    DEV1=ETA(1) 
    DEV2=ETA(2) 
    DEV3=ETA(3) 
  ENDIF  
 
  ; stage1 sub-model 
  IF (MDV1.EQ.0) THEN 
    BPB=268         
 
    BPsb=3.24 
    BPsc=20               
 
    STE1b=-0.447 
    STE2b=-0.52 
    STE3b=-0.463 
 
    STE1c=-0.634 
    STE2c=-0.246 
    STE3c=-3.31 
 
    TVG1A=-0.321 
    TVG2A=-0.0716 
    TVG3A=-4.15 
    TVG1B=-1.07 
    TVG2B=0.492 
    TVG3B=-1.01 
    TVG1C=-1.05 
    TVG2C=-0.251 
    TVG3C=-1.24 
 
    DEV1=ETA(4) 
    DEV2=ETA(5) 
    DEV3=ETA(6) 
  ENDIF   
 
  ; stage2 sub-model 
  IF (MDV2.EQ.0) THEN 
    BPB=676 
 
    BPsb=5.62 
    BPsc=143                
 
    STE1b=-0.905 
    STE2b=-0.894 
    STE3b=-1.19 
    STE4b=-0.993 
 
    STE1c=-1.79 
    STE2c=-6.44 
    STE3c=0.927 
    STE4c=-6.75 
 
    TVG1A=-2.46 103 
 
    TVG2A=-2.52 
    TVG3A=-1.71 
    TVG4A=-4.07 
    TVG1B=-2.57 
    TVG2B=-2.6 
    TVG3B=-3.33 
    TVG4B=-3.34 
    TVG1C=-2.13 
    TVG2C=-2.33 
    TVG3C=-4.59 
    TVG4C=-3.16 
 
    DEV1=ETA(7) 
    DEV2=ETA(8) 
    DEV3=ETA(9) 
    DEV4=ETA(10) 
  ENDIF  
 
  ; sws sub-model 
  IF (MDV3.EQ.0) THEN 
    BPB=715 
 
    BPsb=5.9 
    BPsc=103              
 
    STE1b=-0.999 
    STE2b=-0.939 
    STE3b=-2.5 
 
    STE1c=0.761 
    STE2c=-3.53 
    STE3c=-3.73 
 
    TVG1A=-3.22 
    TVG2A=-4.83 
    TVG3A=-0.526 
    TVG1B=-3.31 
    TVG2B=-5.13 
    TVG3B=0.142 
    TVG1C=-1.65 
    TVG2C=-4.55 
    TVG3C=0.389 
 
    DEV1=ETA(11) 
    DEV2=ETA(12) 
    DEV3=ETA(13) 
  ENDIF  
 
  ; rem sub-model 
  IF (MDV5.EQ.0) THEN 
    BPB=640 
 
    BPsb=13.6 
    BPsc=100              
 
    STE1b=0.351 
    STE2b=-0.238 
    STE3b=-1.22 
 
    STE1c=0.566 
    STE2c=-1.22 . 
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    STE3c=1.8 
 
    TVG1A=-3.12 
    TVG2A=-2.87 
    TVG3A=-3.11 
    TVG1B=-3.25 
    TVG2B=-3.02 
    TVG3B=-4.6 
    TVG1C=-2.96 
    TVG2C=-2.98 
    TVG3C=-4.56 
 
    DEV1=ETA(14) 
    DEV2=ETA(15) 
    DEV3=ETA(16) 
  ENDIF  
 
  G1A=0 
  G2A=0 
  G3A=0 
  G4A=0 
 
  ;-------------------------------- 
  ; stage time effect interpolation 
  ;-------------------------------- 
 
  IF (STT.GE.0.AND.STT.LE.BPsb.AND.SL.EQ.1) THEN 
    G1A=(TVG1A+DEV1)*(BPsb-STT)/(BPsb-BPsa)+(TVG1A+DEV1+STE1b)*(STT-
BPsa)/(BPsb-BPsa) 
    G2A=(TVG2A+DEV2)*(BPsb-STT)/(BPsb-BPsa)+(TVG2A+DEV2+STE2b)*(STT-
BPsa)/(BPsb-BPsa) 
    G3A=(TVG3A+DEV3)*(BPsb-STT)/(BPsb-BPsa)+(TVG3A+DEV3+STE3b)*(STT-
BPsa)/(BPsb-BPsa) 
    G4A=(TVG4A+DEV4)*(BPsb-STT)/(BPsb-BPsa)+(TVG4A+DEV4+STE4b)*(STT-
BPsa)/(BPsb-BPsa) 
 
    G1B=(TVG1B+DEV1)*(BPsb-STT)/(BPsb-BPsa)+(TVG1B+DEV1+STE1b)*(STT-
BPsa)/(BPsb-BPsa) 
    G2B=(TVG2B+DEV2)*(BPsb-STT)/(BPsb-BPsa)+(TVG2B+DEV2+STE2b)*(STT-
BPsa)/(BPsb-BPsa) 
    G3B=(TVG3B+DEV3)*(BPsb-STT)/(BPsb-BPsa)+(TVG3B+DEV3+STE3b)*(STT-
BPsa)/(BPsb-BPsa) 
    G4B=(TVG4B+DEV4)*(BPsb-STT)/(BPsb-BPsa)+(TVG4B+DEV4+STE4b)*(STT-
BPsa)/(BPsb-BPsa) 
 
    G1C=(TVG1C+DEV1)*(BPsb-STT)/(BPsb-BPsa)+(TVG1C+DEV1+STE1b)*(STT-
BPsa)/(BPsb-BPsa) 
    G2C=(TVG2C+DEV2)*(BPsb-STT)/(BPsb-BPsa)+(TVG2C+DEV2+STE2b)*(STT-
BPsa)/(BPsb-BPsa) 
    G3C=(TVG3C+DEV3)*(BPsb-STT)/(BPsb-BPsa)+(TVG3C+DEV3+STE3b)*(STT-
BPsa)/(BPsb-BPsa) 
    G4C=(TVG4C+DEV4)*(BPsb-STT)/(BPsb-BPsa)+(TVG4C+DEV4+STE4b)*(STT-
BPsa)/(BPsb-BPsa) 
  ENDIF 
 
  IF (STT.GT.BPsb.AND.SL.EQ.1) THEN 
    G1A=(TVG1A+DEV1+STE1b)*(BPsc-STT)/(BPsc-
BPsb)+(TVG1A+DEV1+STE1c)*(STT-BPsb)/(BPsc-BPsb) 
    G2A=(TVG2A+DEV2+STE2b)*(BPsc-STT)/(BPsc-
BPsb)+(TVG2A+DEV2+STE2c)*(STT-BPsb)/(BPsc-BPsb) 105 
 
    G3A=(TVG3A+DEV3+STE3b)*(BPsc-STT)/(BPsc-
BPsb)+(TVG3A+DEV3+STE3c)*(STT-BPsb)/(BPsc-BPsb) 
    G4A=(TVG4A+DEV4+STE4b)*(BPsc-STT)/(BPsc-
BPsb)+(TVG4A+DEV4+STE4c)*(STT-BPsb)/(BPsc-BPsb) 
 
    G1B=(TVG1B+DEV1+STE1b)*(BPsc-STT)/(BPsc-
BPsb)+(TVG1B+DEV1+STE1c)*(STT-BPsb)/(BPsc-BPsb) 
    G2B=(TVG2B+DEV2+STE2b)*(BPsc-STT)/(BPsc-
BPsb)+(TVG2B+DEV2+STE2c)*(STT-BPsb)/(BPsc-BPsb) 
    G3B=(TVG3B+DEV3+STE3b)*(BPsc-STT)/(BPsc-
BPsb)+(TVG3B+DEV3+STE3c)*(STT-BPsb)/(BPsc-BPsb) 
    G4B=(TVG4B+DEV4+STE4b)*(BPsc-STT)/(BPsc-
BPsb)+(TVG4B+DEV4+STE4c)*(STT-BPsb)/(BPsc-BPsb) 
 
    G1C=(TVG1C+DEV1+STE1b)*(BPsc-STT)/(BPsc-
BPsb)+(TVG1C+DEV1+STE1c)*(STT-BPsb)/(BPsc-BPsb) 
    G2C=(TVG2C+DEV2+STE2b)*(BPsc-STT)/(BPsc-
BPsb)+(TVG2C+DEV2+STE2c)*(STT-BPsb)/(BPsc-BPsb) 
    G3C=(TVG3C+DEV3+STE3b)*(BPsc-STT)/(BPsc-
BPsb)+(TVG3C+DEV3+STE3c)*(STT-BPsb)/(BPsc-BPsb) 
    G4C=(TVG4C+DEV4+STE4b)*(BPsc-STT)/(BPsc-
BPsb)+(TVG4C+DEV4+STE4c)*(STT-BPsb)/(BPsc-BPsb) 
  ENDIF 
 
;-------------------------------- 
; logits interpolation 
;-------------------------------- 
 
  G1=G1A 
  G2=G2A 
  G3=G3A 
  G4=G4A 
 
  IF (TIME.GE.BPA.AND.TIME.LE.BPB.AND.SL.EQ.1) THEN 
    G1=G1A*(BPB-TIME)/(BPB-BPA)+G1B*(TIME-BPA)/(BPB-BPA) 
    G2=G2A*(BPB-TIME)/(BPB-BPA)+G2B*(TIME-BPA)/(BPB-BPA) 
    G3=G3A*(BPB-TIME)/(BPB-BPA)+G3B*(TIME-BPA)/(BPB-BPA) 
    G4=G4A*(BPB-TIME)/(BPB-BPA)+G4B*(TIME-BPA)/(BPB-BPA) 
  ENDIF 
  IF (TIME.GT.BPB.AND.TIME.LE.BPC.AND.SL.EQ.1) THEN 
    G1=G1B*(BPC-TIME)/(BPC-BPB)+G1C*(TIME-BPB)/(BPC-BPB) 
    G2=G2B*(BPC-TIME)/(BPC-BPB)+G2C*(TIME-BPB)/(BPC-BPB) 
    G3=G3B*(BPC-TIME)/(BPC-BPB)+G3C*(TIME-BPB)/(BPC-BPB) 
    G4=G4B*(BPC-TIME)/(BPC-BPB)+G4C*(TIME-BPB)/(BPC-BPB) 
  ENDIF 
 
  IF (TIME.GE.BP1.AND.TIME.LE.BP2.AND.SL.EQ.0) THEN 
    G1=(TVG11+DEV1)*(BP2-TIME)/(BP2-BP1)+(TVG12+DEV1)*(TIME-BP1)/(BP2-
BP1) 
    G2=(TVG21+DEV2)*(BP2-TIME)/(BP2-BP1)+(TVG22+DEV2)*(TIME-BP1)/(BP2-
BP1) 
    G3=(TVG31+DEV3)*(BP2-TIME)/(BP2-BP1)+(TVG32+DEV3)*(TIME-BP1)/(BP2-
BP1) 
  ENDIF 
  IF (TIME.GT.BP2.AND.SL.EQ.0) THEN 
    G1=(TVG12+DEV1)*(BP3-TIME)/(BP3-BP2)+(TVG13+DEV1)*(TIME-BP2)/(BP3-
BP2) 
    G2=(TVG22+DEV2)*(BP3-TIME)/(BP3-BP2)+(TVG23+DEV2)*(TIME-BP2)/(BP3-
BP2) 
    G3=(TVG32+DEV3)*(BP3-TIME)/(BP3-BP2)+(TVG33+DEV3)*(TIME-BP2)/(BP3-
BP2) . 
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  ENDIF 
 
  ;---------------------------------------- 
  ; transition probabilities as anti-logits 
  ;---------------------------------------- 
 
  PAW=2 
  P1=0 
  P2=0 
  P3=0 
   
  ; awake 
  IF (MDV0.EQ.0) THEN 
    PAW=1/(1+EXP(G1)+EXP(G2)+EXP(G3)) 
    P1=EXP(G1)/(1+EXP(G1)+EXP(G2)+EXP(G3)) 
    P2=EXP(G2)/(1+EXP(G1)+EXP(G2)+EXP(G3)) 
    P3=0 
    PR=EXP(G3)/(1+EXP(G1)+EXP(G2)+EXP(G3)) 
  ENDIF 
 
  ; stage1 
  IF (MDV1.EQ.0) THEN 
    PAW=EXP(G1)/(1+EXP(G1)+EXP(G2)+EXP(G3)) 
    P1=1/(1+EXP(G1)+EXP(G2)+EXP(G3)) 
    P2=EXP(G2)/(1+EXP(G1)+EXP(G2)+EXP(G3)) 
    P3=0 
    PR=EXP(G3)/(1+EXP(G1)+EXP(G2)+EXP(G3)) 
  ENDIF 
 
  ; stage2 
  IF (MDV2.EQ.0) THEN 
    PAW=EXP(G1)/(1+EXP(G1)+EXP(G2)+EXP(G3)+EXP(G4)) 
    P1=EXP(G2)/(1+EXP(G1)+EXP(G2)+EXP(G3)+EXP(G4)) 
    P2=1/(1+EXP(G1)+EXP(G2)+EXP(G3)+EXP(G4)) 
    P3=EXP(G3)/(1+EXP(G1)+EXP(G2)+EXP(G3)+EXP(G4)) 
    PR=EXP(G4)/(1+EXP(G1)+EXP(G2)+EXP(G3)+EXP(G4)) 
  ENDIF 
 
  ; sws 
  IF (MDV3.EQ.0) THEN 
    PAW=EXP(G1)/(1+EXP(G1)+EXP(G2)+EXP(G3)) 
    P1=EXP(G2)/(1+EXP(G1)+EXP(G2)+EXP(G3)) 
    P2=EXP(G3)/(1+EXP(G1)+EXP(G2)+EXP(G3)) 
    P3=1/(1+EXP(G1)+EXP(G2)+EXP(G3)) 
    PR=0 
  ENDIF 
 
  ; rem 
  IF (MDV5.EQ.0) THEN 
    PAW=EXP(G1)/(1+EXP(G1)+EXP(G2)+EXP(G3)) 
    P1=EXP(G2)/(1+EXP(G1)+EXP(G2)+EXP(G3)) 
    P2=EXP(G3)/(1+EXP(G1)+EXP(G2)+EXP(G3)) 
    P3=0 
    PR=1/(1+EXP(G1)+EXP(G2)+EXP(G3)) 
  ENDIF 
   
  ; probability scale 
  DEV1=PAW+P1 
  DEV2=DEV1+P2 
  DEV3=DEV2+P3 
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  ; Initialization of ST; first epoch is awake  
  ST=0    ;stage 
 
  AW=0 
  ST1=0 
  ST2=0 
  ST3=0 
  REM=0 
 
  ; random call for the simulation step 
  IF (ICALL.EQ.4) THEN 
    CALL RANDOM (2,R) 
 
    ; if R<PAW transition to AW is taken into account 
    ; and the following stage is AW(0) 
    IF (R.LT.PAW) THEN 
      ST=0 
      AW=1 
 
    ; if PAW<=R<PAW+P1 transition to ST1 is taken into account 
    ; and the following stage is ST1(1) 
    ELSEIF (R.LT.DEV1.AND.R.GE.PAW) THEN 
      ST=1 
      ST1=1 
 
    ; if PAW+P1<=R<PAW+P1+P2 transition to ST2 is taken into account 
    ; and the following stage is ST2(2) 
    ELSEIF (R.LT.DEV2.AND.R.GE.DEV1) THEN 
      ST=2 
      ST2=1 
 
    ; if PAW+P1+P2<=R<PAW+P1+P2+P3 transition to SWS is  
    ; taken into account and the following stage is SWS(3) 
    ELSEIF (R.LT.DEV3.AND.R.GE.DEV2) THEN 
      ST=3 
      ST3=1 
 
    ; if R>=PAW+P1+P2+P3 transition to REM is  
    ; taken into account and the following stage is REM(5) 
    ELSE 
      ST=5 
      REM=1 
    ENDIF 
  ENDIF 
 
  CH=1                        ;change 
  IF (ST.EQ.PST) CH=0              ; no change 
  PSTT=STT*(CH-1)**2 
 
  IF (TIME.EQ.1) STT=0 
  PSL=SL 
  PST=ST 
 
$THETA 1 
 
;AW 
$OMEGA BLOCK(2) .134 -0.142 .831 
$OMEGA 1.07 
;ST1 
$OMEGA BLOCK(3) .318 .18 .389 -0.0637 .138 .398 
;ST2 . 
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$OMEGA .152 .456 .786 .239 
;ST3 
$OMEGA (0 FIX) 1.4 1.35 
;REM 
$OMEGA .584 .849 1.1 
 
$SIM (123456) (123 UNIFORM) ONLY SUBPROBS=100 NOPREDICTION 
 
$TAB ID VIS TIME ST MDV0 MDV1 MDV2 MDV3 MDV5 MDV 
     AW ST1 ST2 ST3 REM STT EVID SL IS REP 
     ONEHEADER NOPRINT NOAPPEND FILE=simulD1 
 
$TAB ID TIME REP ETA(1) ETA(2) ETA(3) ETA(4) ETA(5) ETA(6) ETA(7) ETA(8) 
    ETA(9) ETA(10) ETA(11) ETA(12) ETA(13) ETA(14) ETA(15) ETA(16) 
     ONEHEADER NOPRINT NOAPPEND FILE=simulE1 
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Appendix B 
R codes 
   
 
 
B.1. Posterior Predictive Check (PPC) 
 
DirData <- "F:\\eem52253\\tesi\\Dati\\"         
DirSim <- 'F:\\eem52253\\tesi\\Dati\\simulation\\' 
 
# raw dataset 
d<-read.csv(paste(DirData, 
            "treatment0Visit33MAD103894forNONMEMallTimes34.csv",sep='')) 
 
ID<-unique(d$ID) 
N<-length(ID) 
 
kmax<-100 
kmax<-kmax+1 
 
# Initialization 
LPS<-matrix(0,nrow=kmax,ncol=N) 
WASO<-matrix(0,nrow=kmax,ncol=N) 
TST<-matrix(0,nrow=kmax,ncol=N) 
tAW<-matrix(0,nrow=kmax,ncol=N) 
tREM<-matrix(0,nrow=kmax,ncol=N) 
tNREM<-matrix(0,nrow=kmax,ncol=N) 
tST1<-matrix(0,nrow=kmax,ncol=N) 
tST2<-matrix(0,nrow=kmax,ncol=N) 
tSWS<-matrix(0,nrow=kmax,ncol=N) 
SE1<-matrix(0,nrow=kmax,ncol=N) 
SE2<-matrix(0,nrow=kmax,ncol=N) 
SE3<-matrix(0,nrow=kmax,ncol=N) 
SE4<-matrix(0,nrow=kmax,ncol=N) 
meanAW<-matrix(0,nrow=kmax,ncol=N) 
meanST1<-matrix(0,nrow=kmax,ncol=N) 
meanST2<-matrix(0,nrow=kmax,ncol=N) 
meanSWS<-matrix(0,nrow=kmax,ncol=N) 
meanREM<-matrix(0,nrow=kmax,ncol=N) 
nAW<-matrix(0,nrow=kmax,ncol=N) 
nST1<-matrix(0,nrow=kmax,ncol=N) 
nST2<-matrix(0,nrow=kmax,ncol=N) 
nSWS<-matrix(0,nrow=kmax,ncol=N) 
nREM<-matrix(0,nrow=kmax,ncol=N) 
 
 
for (k in 1:kmax) { 
  if (k==kmax) 
 { 
 d<-read.csv(paste(DirData, . 
 
110             
 
            "treatment0Visit33MAD103894forNONMEMallTimes34.csv",sep=''))  
 } 
else 
 { 
    d<-read.csv(paste(DirSim, 
            "trt0visit3simulatoForNONMEM34data",k,".csv",sep="")) 
  } 
 
  n<-nrow(d) 
  ID<-unique(d$ID) 
  N<-length(ID) 
 
  for (i in 1:N)  
    { 
    d1<-d[d$ID==ID[i],c(1,3,4)] 
    ll <- nrow(d1) 
     
    d1$SLEEP1<-NA                #=1 from LPS 
    d1$SLEEP<-rep(0,ll) 
 
    d1$STsucc1 <- rep(0,ll) 
    d1$STsucc2 <- rep(0,ll) 
    d1$STsucc3 <- rep(0,ll) 
    d1$STsucc4 <- rep(0,ll) 
    d1$STsucc5 <- rep(0,ll) 
    d1$STsucc6 <- rep(0,ll) 
    d1$STsucc7 <- rep(0,ll) 
    d1$STsucc8 <- rep(0,ll) 
    d1$STsucc9 <- rep(0,ll) 
    d1$STsucc10 <- rep(0,ll) 
    d1$STsucc11 <- rep(0,ll) 
    d1$STsucc12 <- rep(0,ll) 
    d1$STsucc13 <- rep(0,ll) 
    d1$STsucc14 <- rep(0,ll) 
    d1$STsucc15 <- rep(0,ll) 
    d1$STsucc16 <- rep(0,ll) 
    d1$STsucc17 <- rep(0,ll) 
    d1$STsucc18 <- rep(0,ll) 
    d1$STsucc19 <- rep(0,ll) 
 
    d1$STsucc1[1:(ll-1)] <- d1$STAGE[2:ll] 
    d1$STsucc2[1:(ll-2)] <- d1$STAGE[3:ll] 
    d1$STsucc3[1:(ll-3)] <- d1$STAGE[4:ll] 
    d1$STsucc4[1:(ll-4)] <- d1$STAGE[5:ll] 
    d1$STsucc5[1:(ll-5)] <- d1$STAGE[6:ll] 
    d1$STsucc6[1:(ll-6)] <- d1$STAGE[7:ll] 
    d1$STsucc7[1:(ll-7)] <- d1$STAGE[8:ll] 
    d1$STsucc8[1:(ll-8)] <- d1$STAGE[9:ll] 
    d1$STsucc9[1:(ll-9)] <- d1$STAGE[10:ll] 
    d1$STsucc10[1:(ll-10)] <- d1$STAGE[11:ll] 
    d1$STsucc11[1:(ll-11)] <- d1$STAGE[12:ll] 
    d1$STsucc12[1:(ll-12)] <- d1$STAGE[13:ll] 
    d1$STsucc13[1:(ll-13)] <- d1$STAGE[14:ll] 
    d1$STsucc14[1:(ll-14)] <- d1$STAGE[15:ll] 
    d1$STsucc15[1:(ll-15)] <- d1$STAGE[16:ll] 
    d1$STsucc16[1:(ll-16)] <- d1$STAGE[17:ll] 
    d1$STsucc17[1:(ll-17)] <- d1$STAGE[18:ll] 
    d1$STsucc18[1:(ll-18)] <- d1$STAGE[19:ll] 
    d1$STsucc19[1:(ll-19)] <- d1$STAGE[20:ll] 
     
    # at least 20 consecutive ‘non-awake’ stages 111 
 
    d1$SLEEP1 <- (d1$STAGE>0)*(d1$STsucc1>0)*(d1$STsucc2>0)* 
            (d1$STsucc3>0)*(d1$STsucc4>0)*(d1$STsucc5>0)*(d1$STsucc6>0)* 
           (d1$STsucc7>0)*(d1$STsucc8>0)*(d1$STsucc9>0)*(d1$STsucc10>0)* 
        (d1$STsucc11>0)*(d1$STsucc12>0)*(d1$STsucc13>0)*(d1$STsucc14>0)* 
        (d1$STsucc15>0)*(d1$STsucc16>0)*(d1$STsucc17>0)*(d1$STsucc18>0)* 
        (d1$STsucc19>0) 
 
    #----------------------------- 
    # Latency to Persistent Sleep 
    #----------------------------- 
 
    LPS[k,i]<-min(min(which(d1$SLEEP1>0))-1,960) 
 
    if (LPS[k,i]<960)  
        { 
        d1$SLEEP1[(LPS[k,i]+2):ll]<-1 
        } 
    pos<-min((which(d1$STAGE>0)),961) 
     
    if (pos<=ll)  
        { 
        # SLEEP=1 from the first epoch of non-awake 
        d1$SLEEP[(pos):ll]<-1 
        } 
 
    #----------------------------- 
    # Wake After Sleep Onset 
    #----------------------------- 
 
    WASO[k,i]<-sum(d1$STAGE==0 & d1$SLEEP1==1) 
     
    #----------------------------- 
    # Total Sleep Time 
    #----------------------------- 
 
    TST[k,i]<-sum(d1$STAGE!=0) 
 
 
    #---------------------------------- 
    # Total time in each stage  
    #---------------------------------- 
 
    tAW[k,i]<-sum(d1$STAGE==0) 
    tNREM[k,i]<-sum(d1$STAGE<5 & d1$STAGE>0) 
    tREM[k,i]<-sum(d1$STAGE==5) 
    tST1[k,i]<-sum(d1$STAGE==1) 
    tST2[k,i]<-sum(d1$STAGE==2) 
    tSWS[k,i]<-sum(d1$STAGE==3) 
     
    #------------------------------------------------------- 
    # Sleep efficiency on 2-hour time intervals of the night  
    #------------------------------------------------------- 
 
    SE1[k,i]<-sum(d1$STAGE!=0 & d1$Time<241)/240 
    SE2[k,i]<-sum(d1$STAGE!=0 & d1$Time%in%(241:480))/240 
    SE3[k,i]<-sum(d1$STAGE!=0 & d1$Time%in%(481:720))/240 
    SE4[k,i]<-sum(d1$STAGE!=0 & d1$Time%in%(721:960))/240 
     
    # mean extension of awake (after sleep onset) 
    p<-which(d1$STAGE==0 & d1$SLEEP1==1) 
    if (length(p)>0){ . 
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      p1<-c(0,1:nrow(d1),(nrow(d1)+1)) 
      p1<-p1[-(p+1)] 
      pdelta<-p1[2:length(p1)]-p1[1:(length(p1)-1)]-1 
      meanAW[k,i]<-mean(pdelta[pdelta!=0]) 
    } else { 
      meanAW[k,i]<-0 
    } 
 
    # mean extension of stage 1 
    p<-which(d1$STAGE==0 & d1$SLEEP1==1) 
    if (length(p)>0){ 
      p1<-c(0,1:nrow(d1),(nrow(d1)+1)) 
      p1<-p1[-(p+1)] 
      pdelta<-p1[2:length(p1)]-p1[1:(length(p1)-1)]-1 
      meanST1[k,i]<-mean(pdelta[pdelta!=0]) 
    } else { 
      meanST1[k,i]<-0 
    } 
  
    # mean extension of stage 2 
        p<-which(d1$STAGE==0 & d1$SLEEP1==1) 
    if (length(p)>0){ 
      p1<-c(0,1:nrow(d1),(nrow(d1)+1)) 
      p1<-p1[-(p+1)] 
      pdelta<-p1[2:length(p1)]-p1[1:(length(p1)-1)]-1 
      meanST2[k,i]<-mean(pdelta[pdelta!=0]) 
    } else { 
      meanST2[k,i]<-0 
    } 
 
    # mean extension of sws 
    p<-which(d1$STAGE==0 & d1$SLEEP1==1) 
    if (length(p)>0){ 
      p1<-c(0,1:nrow(d1),(nrow(d1)+1)) 
      p1<-p1[-(p+1)] 
      pdelta<-p1[2:length(p1)]-p1[1:(length(p1)-1)]-1 
      meanSWS[k,i]<-mean(pdelta[pdelta!=0]) 
    } else { 
      meanSWS[k,i]<-0 
    } 
 
    # mean extension of rem 
        p<-which(d1$STAGE==0 & d1$SLEEP1==1) 
    if (length(p)>0){ 
      p1<-c(0,1:nrow(d1),(nrow(d1)+1)) 
      p1<-p1[-(p+1)] 
      pdelta<-p1[2:length(p1)]-p1[1:(length(p1)-1)]-1 
      meanREM[k,i]<-mean(pdelta[pdelta!=0]) 
    } else { 
      meanREM[k,i]<-0 
    } 
 
 
    #------------------------------------- 
    # Number of transitions to each stage  
    #------------------------------------- 
 
    nAW[k,i]<-length(which(d1$STAGE!=0 & d1$STsucc1==0)) 
    nST1[k,i]<-length(which(d1$STAGE!=1 & d1$STsucc1==1)) 
    nST2[k,i]<-length(which(d1$STAGE!=2 & d1$STsucc1==2)) 
    nSWS[k,i]<-length(which(d1$STAGE!=3 & d1$STsucc1==3)) 113 
 
    nREM[k,i]<-length(which(d1$STAGE!=5 & d1$STsucc1==5)) 
 
     
  } 
} 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 . 
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B.2. Visual Predictive Check (VPC) 
 
#-----------------------------------------------------------------------
# VPC: transition from AWAKE.   
#----------------------------------------------------------------------- 
 
library(lattice) 
library(vdi) 
 
DirData <- "F:\\eem52253\\tesi\\Dati\\"         
DirSim <- 'F:\\eem52253\\tesi\\Dati\\simulation\\' 
 
 
# samples per subject 
N <- 960 
 
# Time [hours] 
Time <- (1:N)/120 
 
# n=101 raw dataset 
for (n in (1:101)) 
      { 
      if (n==101) 
      { 
      s<-read.csv(paste(DirData, 
            "treatment0Visit33MAD103894forNONMEMallTimes34.csv",sep=''))  
      } 
      else 
      { 
      s<-read.csv(paste(DirSim, 
            "trt0visit3simulatoForNONMEM34data",n,".csv",sep="")) 
      } 
       
      #-----------------------------------     
      # Counting transitions at each epoch  
      #-----------------------------------    
 
      # shift(post) 
      p <- rbind(s[2:nrow(s),],s[1,]) 
 
      d1<-matrix(nrow=960,ncol=51) 
      d1 <- data.frame(d1) 
      names(d1)<- c("times","AW","ST1","ST2","ST3","REM","TRaw1", 
                    "TRaw2","TRaw3","TRawR","TR1aw","TR12","TR13", 
                    "TR1R","TR2aw","TR21","TR23","TR2R","TR3aw", 
                    "TR31","TR32","TR3R","TRRaw","TRR1","TRR2", 
                    "TRR3") 
 
      d1[,1]<-1:N 
 
      # columns d1  
      # 1 times       
      # 2:6 AW,ST1,ST2,SWS,REM: number of occurrences of each stage 
      # 7:26 number of transitions from each stage to each other 
       
 
      for (i in(1:5)) 
        { 
        d1[,1+i] <- tapply(s[,10+i],s$Time,sum) 115 
 
        } 
 
      # temporary data.frame 
      d1t <- s[,c('Time','ID')] 
 
      d1t$TRaw1 <- 0 
      d1t$TRaw2 <- 0 
      d1t$TRaw3 <- 0 
      d1t$TRawR <- 0 
      d1t$TR1aw <- 0 
      d1t$TR12 <- 0 
      d1t$TR13 <- 0 
      d1t$TR1R <- 0 
      d1t$TR2aw <- 0 
      d1t$TR21 <- 0 
      d1t$TR23 <- 0 
      d1t$TR2R <- 0 
      d1t$TR3aw <- 0 
      d1t$TR31 <- 0 
      d1t$TR32 <- 0 
      d1t$TR3R <- 0 
      d1t$TRRaw <- 0 
      d1t$TRR1 <- 0 
      d1t$TRR2 <- 0 
      d1t$TRR3 <- 0 
 
      # transitions for each subject and each Time 
 
      d1t$TRaw1[s$AW==1 & p$ST1==1 & p$MDV==0] <- 1 
      d1t$TRaw2[s$AW==1 & p$ST2==1 & p$MDV==0] <- 1 
      d1t$TRaw3[s$AW==1 & p$ST3==1 & p$MDV==0] <- 1 
      d1t$TRawR[s$AW==1 & p$REM==1 & p$MDV==0] <- 1 
      d1t$TR1aw[s$ST1==1 & p$AW==1 & p$MDV==0] <- 1 
      d1t$TR12[s$ST1==1 & p$ST2==1 & p$MDV==0] <- 1 
      d1t$TR13[s$ST1==1 & p$ST3==1 & p$MDV==0] <- 1 
      d1t$TR1R[s$ST1==1 & p$REM==1 & p$MDV==0] <- 1 
      d1t$TR2aw[s$ST2==1 & p$AW==1 & p$MDV==0] <- 1 
      d1t$TR21[s$ST2==1 & p$ST1==1 & p$MDV==0] <- 1 
      d1t$TR23[s$ST2==1 & p$ST3==1 & p$MDV==0] <- 1 
      d1t$TR2R[s$ST2==1 & p$REM==1 & p$MDV==0] <- 1 
      d1t$TR3aw[s$ST3==1 & p$AW==1 & p$MDV==0] <- 1 
      d1t$TR31[s$ST3==1 & p$ST1==1 & p$MDV==0] <- 1 
      d1t$TR32[s$ST3==1 & p$ST2==1 & p$MDV==0] <- 1 
      d1t$TR3R[s$ST3==1 & p$REM==1 & p$MDV==0] <- 1 
      d1t$TRRaw[s$REM==1 & p$AW==1 & p$MDV==0] <- 1 
      d1t$TRR1[s$REM==1 & p$ST1==1 & p$MDV==0] <- 1 
      d1t$TRR2[s$REM==1 & p$ST2==1 & p$MDV==0] <- 1 
      d1t$TRR3[s$REM==1 & p$ST3==1 & p$MDV==0] <- 1 
       
      # number of transitions for each Time 
      for (i in (1:20)) 
        { 
        d1[,6+i] <- tapply(d1t[,2+i],s$Time,sum) 
        } 
 
     #-------------------------------- 
     # data.frame on 10 Time intervals 
     #-------------------------------- 
      
     # number of intervals 
     n <- 10 . 
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     # samples per interval 
     k <- N/n 
 
     # final data.frame 
     m <- matrix(nrow=10,ncol=51) 
     m <- data.frame(m) 
 
     # temporary data.frame 
     d1t <- d1[1:959,] 
      
     # factor indicating the interval number 
     f <- rep(1:10,each=k) 
     d1t$f <- f[-960] 
      
     # summing each column of transitions on the time intervals 
      for (i in (2:26)) 
        { 
        m[,i] <- tapply(d1t[,i],d1t$f,sum) 
        } 
 
      # interval number 
      m[,1] <- 1:10 
      names(m) <-  c("times","AW","ST1","ST2","ST3","REM","TRaw1", 
                     "TRaw2","TRaw3","TRawR","TR1aw","TR12","TR13", 
                     "TR1R","TR2aw","TR21","TR23","TR2R","TR3aw", 
                     "TR31","TR32","TR3R","TRRaw","TRR1","TRR2","TRR3",                  
                     "Paw1","Paw2","Paw3","PawR","P1aw","P12","P13", 
                     "P1R","P2aw","P21","P23","P2R","P3aw","P31","P32", 
                     "P3R","PRaw","PR1","PR2","PR3","Pawaw","P11", 
                     "P22","P33","PRR") 
 
      # columns m  
      # 1 times       
      # 2:6 AW,ST1,ST2,SWS,REM: number of occurrences on each interval 
      # 7:26 number of transitions from each stage to each other in each 
      #      interval 
      # 27:51 transition frequencies on the intervals 
 
# computing transition frequencies on the 10 intervals 
      m$tot<-1 
      for (i in (1:5)) 
        { 
        m$somma<-0 
        for (j in (1:4)) 
            { 
            k <- 2+4*i+j 
 
            m[,20+k]<-round((m[,k]/m[,1+i]),4) 
            m[is.nan(m[,20+k]),20+k]<-NA 
            m$somma<-m$somma+m[,20+k] 
            } 
        m[,46+i] <-round(m$tot-m$somma,4) 
         
        } 
      # … 
      # m is therefore memorized into a summary file 
      # and iterations continue    
 }# end for n 
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B.3. Visual estimation check(VEC) 
 
 
#-----------------------------------------------------------------------
# VEC on the transition probabilities. Model AWAKE 
#----------------------------------------------------------------------- 
 
library(MASS) 
 
# Linear interpolation 
lininterp <- function(v1,v2,graph=F) { 
 
  lin <- function(x) { 
    if (x[3]!=x[1]) { 
      m <- (x[4]-x[2])/(x[3]-x[1]) 
      k <- (x[3]*x[2]-x[1]*x[4])/(x[3]-x[1]) 
      return(m*(ceiling(x[1]):floor(x[3]))+k) 
    } else return(x[2]) 
  } 
 
  vv <- c(matrix(c(v1,v2),ncol=length(v1),byrow=TRUE)) 
  ww <- seq(from=1,by=2,length=length(v1)-1) 
  zz <- as.data.frame(mapply(':',ww,ww+3)) 
  tt <- lapply(zz,function(x) lin(vv[x])) 
   
  # only if piece-wise linear on two intervals 
  if (vv[zz[1,2]]==round( vv[zz[1,2]])) { 
   tt$V2<-tt$V2[-1] 
  } 
   
  names(tt) <- NULL 
  tt <- c(unlist(tt)) 
 
  return(tt) 
 
} 
 
 
## quantiles 
q25 <- function(x) 
    { 
    return(quantile(x,0.025)) 
    } 
 
q975 <- function(x) 
    { 
    return(quantile(x,0.975)) 
    } 
 
q5 <- function(x) 
    { 
    return(quantile(x,0.05)) 
    } 
 
q95 <- function(x) 
    { 
    return(quantile(x,0.95)) 
    } 
 . 
 
118             
 
 
## m = model number: 
  ## 1: AW 
  m <- 1 
 
  DirSim <- 'D:\\eem52253\\tesi\\Dati\\simulation\\'       
  DirDati <- "D:\\eem52253\\tesi\\Dati\\"         
   
  DF <- read.csv(paste(DirSim,'summary',m,'.csv',sep=''))  
   
  # successfully estimated datasets 
  Yes <- DF$n[DF$su=='Yes'] 
  n <- length(Yes) 
   
  # number of failed minimizations 
  No <- DF$n[DF$su=='No'] 
  NumNo <- length(No) 
   
  # initialization: thetas and omegas 
  nth <- length(grep('TH',names(DF)))/2 
  nom <- length(grep('OM',names(DF)))/2 
    
  TH <- matrix(0,nrow=n,ncol=nth) 
  OM <- matrix(0,nrow=n,ncol=nom) 
   
  # initialization: typical transition probabilities 
  PAp <- matrix(nrow=n,ncol=959) 
  P1p <- matrix(nrow=n,ncol=959) 
  P2p <- matrix(nrow=n,ncol=959) 
  P3p <- matrix(nrow=n,ncol=959) 
  PRp <- matrix(nrow=n,ncol=959) 
 
  # initialization: 95 th percentile on the BSV 
  PApi95 <- matrix(nrow=n,ncol=959) 
  P1pi95 <- matrix(nrow=n,ncol=959) 
  P2pi95 <- matrix(nrow=n,ncol=959) 
  P3pi95 <- matrix(nrow=n,ncol=959) 
  PRpi95 <- matrix(nrow=n,ncol=959) 
   
  # initialization: 5
 th percentile on the BSV 
  PApi5 <- matrix(nrow=n,ncol=959) 
  P1pi5 <- matrix(nrow=n,ncol=959) 
  P2pi5 <- matrix(nrow=n,ncol=959) 
  P3pi5 <- matrix(nrow=n,ncol=959) 
  PRpi5 <- matrix(nrow=n,ncol=959) 
 
  
for (i in 1:n) 
{ 
 #i=n raw dataset 
    # index of the simulated dataset  
    ii <- Yes[i] 
            
    # theta 
    for (j in (1:nth)) 
        { 
        TH[i,j]<-DF[DF$n==ii,paste('TH',j,sep='')] 
        }# end for j 
 
    # omega 
    for (j in 1:nom) 119 
 
      { 
      OM[i,j]<-DF[DF$n==ii,paste('OM',j,sep='')] 
      } # end for j 
 
    # night time BREAK-POINTS after the initial sleeplessness 
    BPA <- medIS    # where medIS is the median IS observed in the data 
    BPC <- 960 
    BPB <- (BPC-BPA)*TH[i,16]+BPA 
     
    BP <- c(BPA,BPB,BPC) 
     
    # Stage time BREAK-POINTS 
    BPsa <- 1 
    BPsc <- maxSTT # maxSTT is the maximum STT observed in the data 
    BPsb <- (BPsc-BPsa)*TH[i,17]+BPsa 
     
    BPs <- c(BPsa,BPsb,BPsc) 
     
    # Initial Sleeplessness BREAK-POINTS 
    BP1 <- 2 
    BP3 <- maxIS # where maxIS is the maximum IS observed in the data 
    BP2 <- (BP3-BP1)*TH[i,18]+BP1 
     
    BPi <- c(BP1,BP2,BP3) 
     
    # Logit 
    G1p <- matrix(0,nrow=1,ncol=959) 
    G2p <- matrix(0,nrow=1,ncol=959) 
    G3p <- matrix(0,nrow=1,ncol=959) 
     
     
    # Linear interpolation of the Stage time effect, MED is the median  
    # STT observed in the data     
    G1Ap <- 
lininterp(BPs,c(TH[i,1],(TH[i,1]+TH[i,10]),(TH[i,1]+TH[i,13])))[MED] 
    G1Bp <- 
lininterp(BPs,c(TH[i,4],(TH[i,4]+TH[i,10]),(TH[i,4]+TH[i,13])))[MED] 
    G1Cp <- 
lininterp(BPs,c(TH[i,7],(TH[i,7]+TH[i,10]),(TH[i,7]+TH[i,13])))[MED] 
     
    G2Ap <- 
lininterp(BPs,c(TH[i,2],(TH[i,2]+TH[i,11]),(TH[i,2]+TH[i,14])))[MED]  
    G2Bp <- 
lininterp(BPs,c(TH[i,5],(TH[i,5]+TH[i,11]),(TH[i,5]+TH[i,14])))[MED] 
    G2Cp <- 
lininterp(BPs,c(TH[i,8],(TH[i,8]+TH[i,11]),(TH[i,8]+TH[i,14])))[MED] 
     
    G3Ap <- 
lininterp(BPs,c(TH[i,3],(TH[i,3]+TH[i,12]),(TH[i,3]+TH[i,15])))[MED] 
    G3Bp <- 
lininterp(BPs,c(TH[i,6],(TH[i,6]+TH[i,12]),(TH[i,6]+TH[i,15])))[MED] 
    G3Cp <- 
lininterp(BPs,c(TH[i,9],(TH[i,9]+TH[i,12]),(TH[i,9]+TH[i,15])))[MED] 
     
    # Linear interpolation of the logits in the second part of the night 
    # (after IS) 
    G1p[(ceiling(BPA)-1):959] <- lininterp(BP,c(G1Ap,G1Bp,G1Cp)) 
    G2p[(ceiling(BPA)-1):959] <- lininterp(BP,c(G2Ap,G2Bp,G2Cp)) 
    G3p[(ceiling(BPA)-1):959] <- lininterp(BP,c(G3Ap,G3Bp,G3Cp)) 
     
    # linear interpolation if the logits in the first part of the night . 
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    G1p[1:(ceiling(BPA)-2)] <- 
lininterp(BPi,c(TH[i,19],TH[i,22],TH[i,25]))[1:(ceiling(BPA)-2)] 
    G2p[1:(ceiling(BPA)-2)] <- 
lininterp(BPi,c(TH[i,20],TH[i,23],TH[i,26]))[1:(ceiling(BPA)-2)] 
    G3p[1:(ceiling(BPA)-2)] <- 
lininterp(BPi,c(TH[i,21],TH[i,24],TH[i,27]))[1:(ceiling(BPA)-2)] 
     
     
    # antilogit 
    PAp[i,] <- 1/(1+exp(G1p)+exp(G2p)+exp(G3p)) 
    P1p[i,] <- exp(G1p)/(1+exp(G1p)+exp(G2p)+exp(G3p)) 
    P2p[i,] <- exp(G2p)/(1+exp(G1p)+exp(G2p)+exp(G3p)) 
    P3p[i,] <- 0 
    PRp[i,] <- exp(G3p)/(1+exp(G1p)+exp(G2p)+exp(G3p)) 
     
                
    #-------------------------------------------------------- 
    ## Between subject variability: 95% prediction intervals 
    #-------------------------------------------------------- 
     
    # simulation of Ns individuals  
    Ns <- 1000 
     
    # covariance matrix 
    COV <- matrix(c(OM[i,1],OM[i,2],OM[i,2],OM[i,3]),nrow=2) 
     
    BSV1 <- mvrnorm(Ns,rep(0,2),COV)[,1] 
    BSV2 <- mvrnorm(Ns,rep(0,2),COV)[,2] 
    BSV3 <- rnorm(Ns,0,sqrt(OM[i,4])) 
    # BSV4 <- fixed to zero 
    # BSV5 <- fixed to zero 
    # BSV6 <- fixed to zero 
     
    BSV1m <- matrix(rep(BSV1,each=(960-(ceiling(BPA)-1)),times=1),  
                    nrow=Ns,byrow=T) 
    BSV2m <- matrix(rep(BSV2,each=(960-(ceiling(BPA)-1)),times=1),  
                    nrow=Ns,byrow=T) 
    BSV3m <- matrix(rep(BSV3,each=(960-(ceiling(BPA)-1)),times=1),  
                    nrow=Ns,byrow=T) 
 
     
    # individual logits: first part of the night 
    G11 <- matrix(rep(G1p[1:(ceiling(BPA)-2)],Ns),nrow=Ns,byrow=T) 
    G21 <- matrix(rep(G2p[1:(ceiling(BPA)-2)],Ns),nrow=Ns,byrow=T) 
    G31 <- matrix(rep(G3p[1:(ceiling(BPA)-2)],Ns),nrow=Ns,byrow=T) 
     
    # individual logits: second part of the night 
    G12 <- matrix(rep(G1p[(ceiling(BPA)-1):959],Ns), 
                 nrow=Ns,byrow=T)+BSV1m 
    G22 <- matrix(rep(G2p[(ceiling(BPA)-1):959],Ns), 
                 nrow=Ns,byrow=T)+BSV2m 
    G32 <- matrix(rep(G3p[(ceiling(BPA)-1):959],Ns), 
                 nrow=Ns,byrow=T)+BSV3m 
     
    # individual logits 
    G1 <- cbind(G11,G12) 
    G2 <- cbind(G21,G22) 
    G3 <- cbind(G31,G32) 
     
    # individual probabilities 
    PA <- 1/(1+exp(G1)+exp(G2)+exp(G3)) 121 
 
    P1 <- exp(G1)/(1+exp(G1)+exp(G2)+exp(G3)) 
    P2 <- exp(G2)/(1+exp(G1)+exp(G2)+exp(G3)) 
    P3 <- matrix(0,nrow=Ns,ncol=959) 
    PR <- exp(G3)/(1+exp(G1)+exp(G2)+exp(G3)) 
     
    # Between subject variability distribution: 90% prediction interval 
    # 95th percentile 
    PApi95[i,] <-  apply(PA,2,q95) 
    P1pi95[i,] <-  apply(P1,2,q95) 
    P2pi95[i,] <-  apply(P2,2,q95) 
    P3pi95[i,] <-  apply(P3,2,q95) 
    PRpi95[i,] <-  apply(PR,2,q95) 
 
    # 5th percentile  
    PApi5[i,] <-  apply(PA,2,q5) 
    P1pi5[i,] <-  apply(P1,2,q5) 
    P2pi5[i,] <-  apply(P2,2,q5) 
    P3pi5[i,] <-  apply(P3,2,q5) 
    PRpi5[i,] <-  apply(PR,2,q5) 
 
} #end for i   
   
  #------------------------    
  ## confidence intervals 
  #------------------------ 
   
  # Typical transition probabilities  
  PAp_down <- apply(PAp[-n,],2,q25) 
  P1p_down <- apply(P1p[-n,],2,q25) 
  P2p_down <- apply(P2p[-n,],2,q25) 
  P3p_down <- apply(P3p[-n,],2,q25) 
  PRp_down <- apply(PRp[-n,],2,q25) 
 
  PAp_up <- apply(PAp[-n,],2,q975) 
  P1p_up <- apply(P1p[-n,],2,q975) 
  P2p_up <- apply(P2p[-n,],2,q975) 
  P3p_up <- apply(P3p[-n,],2,q975) 
  PRp_up <- apply(PRp[-n,],2,q975) 
  
  # median prediction 
  PAp_med <- apply(PAp[-n,],2,median) 
  P1p_med <- apply(P1p[-n,],2,median) 
  P2p_med <- apply(P2p[-n,],2,median) 
  P3p_med <- apply(P3p[-n,],2,median) 
  PRp_med <- apply(PRp[-n,],2,median) 
 
  # 95th percentile BSV  
  PAci95_down <- apply(PAci95[-n,],2,q25) 
  P1ci95_down <- apply(P1ci95[-n,],2,q25) 
  P2ci95_down <- apply(P2ci95[-n,],2,q25) 
  P3ci95_down <- apply(P3ci95[-n,],2,q25) 
  PRci95_down <- apply(PRci95[-n,],2,q25) 
 
  PAci95_up <- apply(PAci95[-n,],2,q975) 
  P1ci95_up <- apply(P1ci95[-n,],2,q975) 
  P2ci95_up <- apply(P2ci95[-n,],2,q975) 
  P3ci95_up <- apply(P3ci95[-n,],2,q975) 
  PRci95_up <- apply(PRci95[-n,],2,q975) 
  
  # median prediction 
  PAci95_med <- apply(PAci95[-n,],2,median) . 
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  P1ci95_med <- apply(P1ci95[-n,],2,median) 
  P2ci95_med <- apply(P2ci95[-n,],2,median) 
  P3ci95_med <- apply(P3ci95[-n,],2,median) 
  PRci95_med <- apply(PRci95[-n,],2,median) 
 
  # 5th percentile 
  PAci5_down <- apply(PAci5[-n,],2,q25) 
  P1ci5_down <- apply(P1ci5[-n,],2,q25) 
  P2ci5_down <- apply(P2ci5[-n,],2,q25) 
  P3ci5_down <- apply(P3ci5[-n,],2,q25) 
  PRci5_down <- apply(PRci5[-n,],2,q25) 
 
  PAci5_up <- apply(PAci5[-n,],2,q975) 
  P1ci5_up <- apply(P1ci5[-n,],2,q975) 
  P2ci5_up <- apply(P2ci5[-n,],2,q975) 
  P3ci5_up <- apply(P3ci5[-n,],2,q975) 
  PRci5_up <- apply(PRci5[-n,],2,q975) 
 
  # median prediction 
  PAci5_med <- apply(PAci5[-n,],2,median) 
  P1ci5_med <- apply(P1ci5[-n,],2,median) 
  P2ci5_med <- apply(P2ci5[-n,],2,median) 
  P3ci5_med <- apply(P3ci5[-n,],2,median) 
  PRci5_med <- apply(PRci5[-n,],2,median) 
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